Document:

Exhibit 45

		

			Exhibit 4.5

		

		
			﻿
		

			
					
						﻿

				
	
					
						﻿

				

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			Aratana Therapeutics, Inc.
		

		
			_________________________
		

		
			INDENTURE
		

		
			Dated as of ___________, 20__
		

		
			_________________________
		

		
			Wilmington Trust, National Association
		

		
			Trustee
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

			
					
						﻿

				
	
					
						﻿

				

		
			﻿
		

		
			﻿
		

		
			 
		

		
			
		

		 

 

		

			 

		

		TABLE OF CONTENTS
		

		
			﻿
		

			
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						Page

				
	
					
						﻿ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE

					
					
						1

				
	
					
						﻿Section 1.1. 

					
					
						Definitions.

					
					
						1

				
	
					
						﻿Section 1.2. 

					
					
						Other Definitions.

					
					
						4

				
	
					
						﻿Section 1.3. 

					
					
						Incorporation by Reference of Trust Indenture Act.

					
					
						4

				
	
					
						﻿Section 1.4. 

					
					
						Rules of Construction.

					
					
						5

				
	
					
						﻿ARTICLE II. THE SECURITIES

					
					
						5

				
	
					
						﻿Section 2.1. 

					
					
						Issuable in Series.

					
					
						5

				
	
					
						﻿Section 2.2. 

					
					
						Establishment of Terms of Series of Securities.

					
					
						6

				
	
					
						﻿Section 2.3. 

					
					
						Execution and Authentication.

					
					
						8

				
	
					
						﻿Section 2.4. 

					
					
						Registrar and Paying Agent.

					
					
						9

				
	
					
						﻿Section 2.5. 

					
					
						Paying Agent to Hold Money in Trust.

					
					
						10

				
	
					
						﻿Section 2.6. 

					
					
						Securityholder Lists.

					
					
						10

				
	
					
						﻿Section 2.7. 

					
					
						Transfer and Exchange.

					
					
						10

				
	
					
						﻿Section 2.8. 

					
					
						Mutilated, Destroyed, Lost and Stolen Securities.

					
					
						10

				
	
					
						﻿Section 2.9. 

					
					
						Outstanding Securities.

					
					
						11

				
	
					
						﻿Section 2.10. 

					
					
						Treasury Securities.

					
					
						12

				
	
					
						﻿Section 2.11. 

					
					
						Temporary Securities.

					
					
						12

				
	
					
						﻿Section 2.12. 

					
					
						Cancellation.

					
					
						12

				
	
					
						﻿Section 2.13. 

					
					
						Defaulted Interest.

					
					
						12

				
	
					
						﻿Section 2.14. 

					
					
						Global Securities.

					
					
						13

				
	
					
						﻿Section 2.15. 

					
					
						CUSIP Numbers.

					
					
						14

				
	
					
						﻿Section 2.16. 

					
					
						Trustee Not Responsible for Securities Laws.

					
					
						14

				
	
					
						﻿ARTICLE III. REDEMPTION

					
					
						15

				
	
					
						﻿Section 3.1. 

					
					
						Notice to Trustee.

					
					
						15

				
	
					
						﻿Section 3.2. 

					
					
						Selection of Securities to be Redeemed.

					
					
						15

				
	
					
						﻿Section 3.3. 

					
					
						Notice of Redemption.

					
					
						15

				
	
					
						﻿Section 3.4. 

					
					
						Effect of Notice of Redemption.

					
					
						16

				
	
					
						﻿Section 3.5. 

					
					
						Deposit of Redemption Price.

					
					
						16

				
	
					
						﻿Section 3.6. 

					
					
						Securities Redeemed in Part.

					
					
						16

				
	
					
						﻿ARTICLE IV. COVENANTS

					
					
						17

				
	
					
						﻿Section 4.1. 

					
					
						Payment of Principal and Interest.

					
					
						17

				
	
					
						﻿Section 4.2. 

					
					
						SEC Reports.

					
					
						17

				
	
					
						﻿Section 4.3. 

					
					
						Compliance Certificate.

					
					
						17

				
	
					
						﻿Section 4.4. 

					
					
						Stay, Extension and Usury Laws.

					
					
						17

				
	
					
						﻿ARTICLE V. SUCCESSORS

					
					
						18

				
	
					
						﻿Section 5.1. 

					
					
						When Company May Merge, Etc.

					
					
						18

				
	
					
						﻿Section 5.2. 

					
					
						Successor Corporation Substituted.

					
					
						18

				

		
			﻿
		

		
			 
		

		

		

		 

		

			i

		

 

		

			 

		

		﻿
		

			
					
						﻿ARTICLE VI. DEFAULTS AND REMEDIES

					
					
						19

				
	
					
						﻿Section 6.1. 

					
					
						Events of Default.

					
					
						19

				
	
					
						﻿Section 6.2. 

					
					
						Acceleration of Maturity; Rescission and Annulment.

					
					
						20

				
	
					
						﻿Section 6.3. 

					
					
						Collection of Indebtedness and Suits for Enforcement by Trustee.

					
					
						21

				
	
					
						﻿Section 6.4. 

					
					
						Trustee May File Proofs of Claim.

					
					
						21

				
	
					
						﻿Section 6.5. 

					
					
						Trustee May Enforce Claims Without Possession of Securities.

					
					
						22

				
	
					
						﻿Section 6.6. 

					
					
						Application of Money Collected.

					
					
						22

				
	
					
						﻿Section 6.7. 

					
					
						Limitation on Suits.

					
					
						23

				
	
					
						﻿Section 6.8. 

					
					
						Unconditional Right of Holders to Receive Principal and Interest.

					
					
						23

				
	
					
						﻿Section 6.9. 

					
					
						Restoration of Rights and Remedies.

					
					
						23

				
	
					
						﻿Section 6.10. 

					
					
						Rights and Remedies Cumulative.

					
					
						24

				
	
					
						﻿Section 6.11. 

					
					
						Delay or Omission Not Waiver.

					
					
						24

				
	
					
						﻿Section 6.12. 

					
					
						Control by Holders.

					
					
						24

				
	
					
						﻿Section 6.13. 

					
					
						Waiver of Past Defaults.

					
					
						25

				
	
					
						﻿Section 6.14. 

					
					
						Undertaking for Costs.

					
					
						25

				
	
					
						﻿ARTICLE VII. TRUSTEE

					
					
						25

				
	
					
						﻿Section 7.1. 

					
					
						Duties of Trustee.

					
					
						25

				
	
					
						﻿Section 7.2. 

					
					
						Rights of Trustee.

					
					
						26

				
	
					
						﻿Section 7.3. 

					
					
						Individual Rights of Trustee.

					
					
						28

				
	
					
						﻿Section 7.4. 

					
					
						Trustee’s Disclaimer.

					
					
						28

				
	
					
						﻿Section 7.5. 

					
					
						Notice of Defaults.

					
					
						28

				
	
					
						﻿Section 7.6. 

					
					
						Reports by Trustee to Holders.

					
					
						28

				
	
					
						﻿Section 7.7. 

					
					
						Compensation and Indemnity.

					
					
						29

				
	
					
						﻿Section 7.8. 

					
					
						Replacement of Trustee.

					
					
						30

				
	
					
						﻿Section 7.9. 

					
					
						Successor Trustee by Merger, Etc.

					
					
						31

				
	
					
						﻿Section 7.10. 

					
					
						Eligibility; Disqualification.

					
					
						31

				
	
					
						﻿Section 7.11. 

					
					
						Preferential Collection of Claims Against Company.

					
					
						31

				
	
					
						﻿ARTICLE VIII. SATISFACTION AND DISCHARGE; DEFEASANCE

					
					
						31

				
	
					
						﻿Section 8.1. 

					
					
						Satisfaction and Discharge of Indenture.

					
					
						31

				
	
					
						﻿Section 8.2. 

					
					
						Application of Trust Funds; Indemnification.

					
					
						32

				
	
					
						﻿Section 8.3. 

					
					
						Legal Defeasance of Securities of any Series.

					
					
						33

				
	
					
						﻿Section 8.4. 

					
					
						Covenant Defeasance.

					
					
						34

				
	
					
						﻿Section 8.5. 

					
					
						Repayment to Company.

					
					
						35

				
	
					
						﻿Section 8.6. 

					
					
						Reinstatement.

					
					
						35

				
	
					
						﻿ARTICLE IX. AMENDMENTS AND WAIVERS

					
					
						36

				
	
					
						﻿Section 9.1. 

					
					
						Without Consent of Holders.

					
					
						36

				
	
					
						﻿Section 9.2. 

					
					
						With Consent of Holders.

					
					
						37

				
	
					
						﻿Section 9.3. 

					
					
						Limitations.

					
					
						37

				
	
					
						﻿Section 9.4. 

					
					
						Compliance with Trust Indenture Act.

					
					
						38

				
	
					
						﻿Section 9.5. 

					
					
						Revocation and Effect of Consents.

					
					
						38

				
	
					
						﻿Section 9.6. 

					
					
						Notation on or Exchange of Securities.

					
					
						38

				
	
					
						﻿Section 9.7. 

					
					
						Trustee Protected.

					
					
						38

				

		
			﻿
		

		
			 
		

		

		

		 

		

			ii

		

 

		

			 

		

		﻿
		

			
					
						﻿ARTICLE X. MISCELLANEOUS

					
					
						39

				
	
					
						﻿Section 10.1. 

					
					
						Trust Indenture Act Controls.

					
					
						39

				
	
					
						﻿Section 10.2. 

					
					
						Notices.

					
					
						39

				
	
					
						﻿Section 10.3. 

					
					
						Communication by Holders with Other Holders.

					
					
						40

				
	
					
						﻿Section 10.4. 

					
					
						Certificate and Opinion as to Conditions Precedent.

					
					
						40

				
	
					
						﻿Section 10.5. 

					
					
						Statements Required in Certificate or Opinion.

					
					
						40

				
	
					
						﻿Section 10.6. 

					
					
						Rules by Trustee and Agents.

					
					
						41

				
	
					
						﻿Section 10.7. 

					
					
						Legal Holidays.

					
					
						41

				
	
					
						﻿Section 10.8. 

					
					
						No Recourse Against Others.

					
					
						41

				
	
					
						﻿Section 10.9. 

					
					
						Counterparts.

					
					
						41

				
	
					
						﻿Section 10.10. 

					
					
						Governing Law; Waiver of Jury Trial; Consent to Jurisdiction.

					
					
						41

				
	
					
						﻿Section 10.11. 

					
					
						No Adverse Interpretation of Other Agreements.

					
					
						42

				
	
					
						﻿Section 10.12. 

					
					
						Successors.

					
					
						42

				
	
					
						﻿Section 10.13. 

					
					
						Severability.

					
					
						42

				
	
					
						﻿Section 10.14. 

					
					
						Table of Contents, Headings, Etc.

					
					
						42

				
	
					
						﻿Section 10.15. 

					
					
						Securities in a Foreign Currency.

					
					
						42

				
	
					
						﻿Section 10.16. 

					
					
						Judgment Currency.

					
					
						43

				
	
					
						﻿Section 10.17. 

					
					
						Force Majeure.

					
					
						44

				
	
					
						﻿Section 10.18. 

					
					
						U.S.A. Patriot Act.

					
					
						44

				
	
					
						﻿ARTICLE XI. SINKING FUNDS

					
					
						44

				
	
					
						﻿Section 11.1. 

					
					
						Applicability of Article.

					
					
						44

				
	
					
						﻿Section 11.2. 

					
					
						Satisfaction of Sinking Fund Payments with Securities.

					
					
						44

				
	
					
						﻿Section 11.3. 

					
					
						Redemption of Securities for Sinking Fund.

					
					
						45

				

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			 
		

		

		

		 

		

			iii

		

 

		

			 

		

		Aratana Therapeutics, Inc.
		

		
			Reconciliation and tie between Trust Indenture Act of 1939 and
Indenture, dated as of ____________, 20__
		

		
			﻿
		

			
					
						﻿

					
					
						 

					
					
						 

				
	
					
						§ 310(a)(1)

					
					
						........................................................................

					
					
						7.10

				
	
					
						(a)(2)

					
					
						........................................................................

					
					
						7.10

				
	
					
						(a)(3)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						(a)(4)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						(a)(5)

					
					
						........................................................................

					
					
						7.10

				
	
					
						(b)

					
					
						........................................................................

					
					
						7.10

				
	
					
						§ 311(a)

					
					
						........................................................................

					
					
						7.11

				
	
					
						(b)

					
					
						........................................................................

					
					
						7.11

				
	
					
						(c)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						§ 312(a)

					
					
						........................................................................

					
					
						2.6

				
	
					
						(b)

					
					
						........................................................................

					
					
						10.3

				
	
					
						(c)

					
					
						........................................................................

					
					
						10.3

				
	
					
						§ 313(a)

					
					
						........................................................................

					
					
						7.6

				
	
					
						(b)(1)

					
					
						........................................................................

					
					
						7.6

				
	
					
						(b)(2)

					
					
						........................................................................

					
					
						7.6

				
	
					
						(c)(1)

					
					
						........................................................................

					
					
						7.6

				
	
					
						(d)

					
					
						........................................................................

					
					
						7.6

				
	
					
						§ 314(a)

					
					
						........................................................................

					
					
						4.2, 10.5

				
	
					
						(b)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						(c)(1)

					
					
						........................................................................

					
					
						10.40

				
	
					
						(c)(2)

					
					
						........................................................................

					
					
						10.40

				
	
					
						(c)(3)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						(d)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						(e)

					
					
						........................................................................

					
					
						10.50

				
	
					
						(f)

					
					
						........................................................................

					
					
						Not Applicable

				
	
					
						§ 315(a)

					
					
						........................................................................

					
					
						7.1

				
	
					
						(b)

					
					
						........................................................................

					
					
						7.5

				
	
					
						(c)

					
					
						........................................................................

					
					
						7.1

				
	
					
						(d)

					
					
						........................................................................

					
					
						7.1

				
	
					
						(e)

					
					
						........................................................................

					
					
						6.1

				
	
					
						§ 316(a)

					
					
						........................................................................

					
					
						2.1

				
	
					
						(a)(1)(A)

					
					
						........................................................................

					
					
						6.1

				
	
					
						(a)(1)(B)

					
					
						........................................................................

					
					
						6.1

				
	
					
						(b)

					
					
						........................................................................

					
					
						6.8

				
	
					
						         § 317(a)(1)

					
					
						........................................................................

					
					
						6.3

				
	
					
						(a)(2)

					
					
						........................................................................

					
					
						6.4

				
	
					
						(b)

					
					
						........................................................................

					
					
						2.5

				
	
					
						§ 318(a)

					
					
						........................................................................

					
					
						10.1

				

		
			____________________
		

		
			Note:  This reconciliation and tie shall not, for any purpose, be deemed to be part of the Indenture.
		

		
			﻿
		

		
			 
		

		

		

		 

		

			iv

		

 

		

			Table of Contents

		

		

			 

		

		Indenture dated as of __________, 20__ between Aratana Therapeutics, Inc., a company incorporated under the laws of Delaware (“Company”), and Wilmington Trust, National Association (“Trustee”).
		

		
			Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.
		

		
			ARTICLE I.
		

		
			DEFINITIONS AN D INCORPORATION BY REFERENCE
		

		
			﻿
		

		
			Section 1.1.   Definitions.
		

		
			“Affiliate” of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified person.   For the purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to any person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities or by agreement or otherwise.
		

		
			“Agent” means any Registrar, Paying Agent or Notice Agent.
		

		
			“Board of Directors” means the board of directors of the Company or any duly authorized committee thereof.
		

		
			“Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to the Trustee.
		

		
			“Business Day” means any day except a Saturday, Sunday or a legal holiday in The City of New York, New York (or in connection with any payment, the place of payment) on which banking institutions are authorized or required by law, regulation or executive order to close.
		

		
			“Capital Stock” means any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock.
		

		
			“Company” means the party named as such above until a successor replaces it and thereafter means the successor.
		

		
			“Company Order” means a written order signed in the name of the Company by an Officer.
		

		
			“Corporate Trust Office” means the office of the Trustee at which at any particular time its corporate trust business related to this Indenture shall be principally administered.
		

		
			“Default” means any event which is, or after notice or passage of time or both would be, an Event of Default.
		

		 

		

			 

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			“Depositary” means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency registered under the Exchange Act; and if at any time there is more than one such person, “Depositary” as used with respect to the Securities of any Series shall mean the Depositary with respect to the Securities of such Series.
		

		
			“Discount Security” means any Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2.
		

		
			“Dollars” and “$” means the currency of The United States of America.
		

		
			“Exchange Act” means the Securities Exchange Act of 1934, as amended.
		

		
			“Foreign Currency” means any currency or currency unit issued by a government other than the government of The United States of America.
		

		
			“Foreign Government Obligations” means, with respect to Securities of any Series that are denominated in a Foreign Currency, direct obligations of, or obligations guaranteed by, the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof.
		

		
			“GAAP” means accounting principles generally accepted in the United States of America set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination.
		

		
			“Global Security” or “Global Securities” means a Security or Securities, as the case may be, in the form established pursuant to Section 2.2 evidencing all or part of a Series of Securities, issued to the Depositary for such Series or its nominee, and registered in the name of such Depositary or nominee.
		

		
			“Holder” or “Securityholder” means a person in whose name a Security is registered.
		

		
			“Indenture” means this Indenture as amended or supplemented from time to time and shall include the form and terms of particular Series of Securities established as contemplated hereunder.
		

		
			“interest” with respect to any Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.
		

		 

		

			2

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			“Maturity,” when used with respect to any Security, means the date on which the principal of such Security becomes due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise.
		

		
			“Officer” means the Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Assistant Treasurer, the Secretary or any Assistant Secretary, and any Vice President of the Company, whether or not designated by a number or numbers or a word or words added after the title “Vice President”.
		

		
			“Officer’s Certificate” means a certificate signed by any Officer.
		

		
			“Opinion of Counsel” means a written opinion of legal counsel who is acceptable to the Trustee.  The counsel may be an employee of or counsel to the Company. The opinion may contain customary limitations, conditions and exceptions. 
		

		
			“person” means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.
		

		
			“principal” of a Security means the principal of the Security plus, when appropriate, the premium, if any, on the Security.
		

		
			“Responsible Officer” means, when used with respect to the Trustee, any officer of the Trustee in its Corporate Trust Office and also means, with respect to a particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with a particular subject, and, in each case, who shall have direct responsibility for the administration of this Indenture.
		

		
			“SEC” means the Securities and Exchange Commission.
		

		
			“Securities” means the debentures, notes or other debt instruments of the Company of any Series authenticated and delivered under this Indenture.
		

		
			“Series” or “Series of Securities” means each series of debentures, notes or other debt instruments of the Company created pursuant to Sections 2.1 and 2.2 hereof.
		

		
			“Stated Maturity” when used with respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security or interest is due and payable.
		

		
			“Subsidiary” of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof.
		

		
			“TIA” means the Trust Indenture Act of 1939 (15 U.S. Code §§ 77aaa-77bbbb) as in effect on the date of this Indenture; provided,  however, that in the event the Trust Indenture Act of 1939 is amended after such date, “TIA” means, to the extent required by any such amendment, the Trust Indenture Act as so amended.
		

		 

		

			3

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			“Trustee” means the person named as the “Trustee” in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean or include each person who is then a Trustee hereunder, and if at any time there is more than one such person, “Trustee” as used with respect to the Securities of any Series shall mean the Trustee with respect to Securities of that Series.
		

		
			“U.S. Government Obligations” means securities which are direct obligations of, or guaranteed by, The United States of America for the payment of which its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest on or principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depository receipt, provided that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such depositary receipt.
		

		
			Section 1.2.   Other Definitions.
		

		
			 
		

			
					
						﻿

					
					
						 

				
	
					
						TERM

					
					
						DEFINED IN

				
	
					
						﻿

					
					
						SECTION

				
	
					
						“Bankruptcy Law”

					
					
						6.1

				
	
					
						“Custodian”

					
					
						6.1

				
	
					
						“Event of Default”

					
					
						6.1

				
	
					
						“Judgment Currency”

					
					
						10.16

				
	
					
						“Legal Holiday”

					
					
						10.7

				
	
					
						“mandatory sinking fund payment”

					
					
						11.1

				
	
					
						“New York Banking Day”

					
					
						10.16

				
	
					
						“Notice Agent”

					
					
						2.4

				
	
					
						“optional sinking fund payment”

					
					
						11.1

				
	
					
						“Paying Agent”

					
					
						2.4

				
	
					
						“Registrar”

					
					
						2.4

				
	
					
						“Required Currency”

					
					
						10.16

				
	
					
						“Specified Courts”

					
					
						10.10

				
	
					
						“successor person”

					
					
						5.1

				

		
			﻿
		

		
			Section 1.3.   Incorporation by Reference of Trust Indenture Act.
		

		
			Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture.  The following TIA terms used in this Indenture have the following meanings:
		

		
			“Commission” means the SEC.
		

		 

		

			4

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			“indenture securities” means the Securities.
		

		
			“indenture security holder” means a Securityholder.
		

		
			“indenture to be qualified” means this Indenture.
		

		
			“indenture trustee” or “institutional trustee” means the Trustee.
		

		
			“obligor” on the indenture securities means the Company and any successor obligor upon the Securities.
		

		
			All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under the TIA and not otherwise defined herein are used herein as so defined.
		

		
			Section 1.4.   Rules of Construction.
		

		
			Unless the context otherwise requires:
		

		
			(a)     a term has the meaning assigned to it;
		

		
			(b)     an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;
		

		
			(c)     “or” is not exclusive;
		

		
			(d)     words in the singular include the plural, and in the plural include the singular; and
		

		
			(e)     provisions apply to successive events and transactions.
		

		
			ARTICLE II.
THE SECURITIES
		

		
			﻿
		

		
			Section 2.1.   Issuable in Series.
		

		
			The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited.  The Securities may be issued in one or more Series. All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a supplemental indenture or an Officer’s Certificate detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officer’s Certificate or supplemental indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are to be determined.  Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture.
		

		 

		

			5

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 2.2.   Establishment of Terms of Series of Securities.
		

		
			At or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series generally, in the case of Subsection 2.2.1 and either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2.2 through 2.2.23) by or pursuant to a Board Resolution, and set forth or determined in the manner provided in a Board Resolution, supplemental indenture hereto or Officer’s Certificate:
		

		
			2.2.1.     the title (which shall distinguish the Securities of that particular Series from the Securities of any other Series) and ranking (including the terms of any subordination provisions) of the Series;
		

		
			2.2.2.     the price or prices (expressed as a percentage of the principal amount thereof) at which the Securities of the Series will be issued;
		

		
			2.2.3.     any limit upon the aggregate principal amount of the Securities of the Series which may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 9.6);
		

		
			2.2.4.     the date or dates on which the principal of the Securities of the Series is payable;
		

		
			2.2.5.     the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including, but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall bear interest, if any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if any, shall commence and be payable and any regular record date for the interest payable on any interest payment date;
		

		
			2.2.6.     the place or places where the principal of and interest, if any, on the Securities of the Series shall be payable, where the Securities of such Series may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered, and the method of such payment, if by wire transfer, mail or other means;
		

		
			2.2.7.     if applicable, the period or periods within which, the price or prices at which and the terms and conditions upon which the Securities of the Series may be redeemed, in whole or in part, at the option of the Company;
		

		
			2.2.8.     the obligation, if any, of the Company to redeem or purchase the Securities of the Series pursuant to any sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation; 
		

		 

		

			6

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			2.2.9.     the dates, if any, on which and the price or prices at which the Securities of the Series will be repurchased by the Company at the option of the Holders thereof and other detailed terms and provisions of such repurchase obligations;
		

		
			2.2.10.     if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series shall be issuable;
		

		
			2.2.11.     the forms of the Securities of the Series and whether the Securities will be issuable as Global Securities;
		

		
			2.2.12.     if other than the principal amount thereof, the portion of the principal amount of the Securities of the Series that shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2;
		

		
			2.2.13.     the currency of denomination of the Securities of the Series, which may be Dollars or any Foreign Currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency;
		

		
			2.2.14.     the designation of the currency, currencies or currency units in which payment of the principal of and interest, if any, on the Securities of the Series will be made;
		

		
			2.2.15.     if payments of principal of or interest, if any, on the Securities of the Series are to be made in one or more currencies or currency units other than that or those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined;
		

		
			2.2.16.     the manner in which the amounts of payment of principal of or interest, if any, on the Securities of the Series will be determined, if such amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index;
		

		
			2.2.17.     the provisions, if any, relating to any security provided for the Securities of the Series;
		

		
			2.2.18.     any addition to, deletion of or change in the Events of Default which applies to any Securities of the Series and any change in the right of the Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;
		

		
			2.2.19.     any addition to, deletion of or change in the covenants set forth in Articles IV or V which applies to Securities of the Series;
		

		
			2.2.20.     any Depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such Series if other than those appointed herein;
		

		
			2.2.21.     the provisions, if any, relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion 
		

		 

		

			7

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the option of the Company, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such Series of Securities are redeemed;
		

		
			2.2.22.     any other terms of the Series (which may supplement, modify or delete any provision of this Indenture insofar as it applies to such Series), including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series; and
		

		
			2.2.23.     whether any of the Company’s direct or indirect Subsidiaries will guarantee the Securities of that Series, including the terms of subordination, if any, of such guarantees.
		

		
			All Securities of any one Series need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officer’s Certificate referred to above.
		

		
			Section 2.3.   Execution and Authentication.
		

		
			An Officer shall sign the Securities for the Company by manual or facsimile signature. 
		

		
			If an Officer whose signature is on a Security no longer holds that office at the time the Security is authenticated, the Security shall nevertheless be valid.
		

		
			A Security shall not be valid until authenticated by the manual signature of the Trustee or an authenticating agent.  The signature shall be conclusive evidence that the Security has been authenticated under this Indenture.
		

		
			The Trustee shall at any time, and from time to time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto or Officer’s Certificate, upon receipt by the Trustee of a Company Order.  Each Security shall be dated the date of its authentication.
		

		
			The aggregate principal amount of Securities of any Series outstanding at any time may not exceed any limit upon the maximum principal amount for such Series set forth in the Board Resolution, supplemental indenture hereto or Officer’s Certificate delivered pursuant to Section 2.2, except as provided in Section 2.8.
		

		
			Prior to the issuance of Securities of any Series, the Trustee shall have received and (subject to Section 7.2) shall be fully protected in relying on:  (a) the Board Resolution, supplemental indenture hereto or Officer’s Certificate establishing the form of the Securities of that Series or of Securities within that Series and the terms of the Securities of that Series or of Securities within that Series, (b) an Officer’s Certificate complying with Section 10.4, and (c) an Opinion of Counsel complying with Section 10.4.
		

		 

		

			8

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			The Trustee shall have the right to decline to authenticate and deliver any Securities of such Series: (a) if the Trustee, being advised by counsel, determines that such action may not be taken lawfully; or (b) if the Trustee in good faith by its board of directors or trustees, executive committee or a trust committee of directors and/or vice-presidents or a committee of Responsible Officers shall determine that such action would expose the Trustee to personal liability to Holders of any then outstanding Series of Securities.
		

		
			The Trustee may appoint an authenticating agent acceptable to the Company to authenticate Securities.  An authenticating agent may authenticate Securities whenever the Trustee may do so.  Each reference in this Indenture to authentication by the Trustee includes authentication by such agent.  An authenticating agent has the same rights as an Agent to deal with the Company or an Affiliate of the Company.
		

		
			Section 2.4.   Registrar and Paying Agent.
		

		
			The Company shall maintain, with respect to each Series of Securities, at the place or places specified with respect to such Series pursuant to Section 2.2, an office or agency where Securities of such Series may be presented or surrendered for payment (“Paying Agent”), where Securities of such Series may be surrendered for registration of transfer or exchange (“Registrar”) and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered (“Notice Agent”).  The Registrar shall keep a register with respect to each Series of Securities and to their transfer and exchange.  The Company will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar, Paying Agent or Notice Agent.  If at any time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent or shall fail to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands; provided,  however, that any appointment of the Trustee as the Notice Agent shall exclude the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company.
		

		
			The Company may also from time to time designate one or more co-registrars, additional paying agents or additional notice agents and may from time to time rescind such designations; provided,  however, that no such designation or rescission shall in any manner relieve the Company of its obligations to maintain a Registrar, Paying Agent and Notice Agent in each place so specified pursuant to Section 2.2 for Securities of any Series for such purposes.  The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address of any such co-registrar, additional paying agent or additional notice agent.  The term “Registrar” includes any co-registrar; the term “Paying Agent” includes any additional paying agent; and the term “Notice Agent” includes any additional notice agent.  The Company or any of its Affiliates may serve as Registrar or Paying Agent.
		

		
			The Company hereby appoints the Trustee the initial Registrar, Paying Agent and Notice Agent for each Series unless another Registrar, Paying Agent or Notice Agent, as the case may be, is appointed prior to the time Securities of that Series are first issued.
		

		 

		

			9

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 2.5.   Paying Agent to Hold Money in Trust.
		

		
			The Company shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Securityholders of any Series of Securities, or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series of Securities, and will notify the Trustee in writing of any default by the Company in making any such payment.  While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee.  The Company at any time may require a Paying Agent to pay all money held by it to the Trustee.  Upon payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary of the Company) shall have no further liability for the money.  If the Company or a Subsidiary of the Company acts as Paying Agent, it shall segregate and hold in a separate trust fund for the benefit of Securityholders of any Series of Securities all money held by it as Paying Agent.  Upon any bankruptcy, reorganization or similar proceeding with respect to the Company, the Trustee shall serve as Paying Agent for the Securities.
		

		
			Section 2.6.   Securityholder Lists.
		

		
			The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Securityholders of each Series of Securities and shall otherwise comply with TIA  § 312(a).  If the Trustee is not the Registrar, the Company shall furnish to the Trustee at least ten days before each interest payment date and at such other times as the Trustee may request in writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Securityholders of each Series of Securities.
		

		
			Section 2.7.   Transfer and Exchange.
		

		
			Where Securities of a Series are presented to the Registrar or a co-registrar with a request to register a transfer or to exchange them for an equal principal amount of Securities of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met.  To permit registrations of transfers and exchanges, the Trustee shall authenticate Securities at the Registrar’s request.  No service charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than any such transfer tax or similar governmental charge payable upon exchanges pursuant to Sections 2.11, 3.6 or 9.6).
		

		
			Neither the Company nor the Registrar shall be required (a) to issue, register the transfer of, or exchange Securities of any Series for the period beginning at the opening of business fifteen days immediately preceding the sending of a notice of redemption of Securities of that Series selected for redemption and ending at the close of business on the day such notice is sent, or (b) to register the transfer of or exchange Securities of any Series selected, called or being called for redemption as a whole or the portion being redeemed of any such Securities selected, called or being called for redemption in part.
		

		
			Section 2.8.   Mutilated, Destroyed, Lost and Stolen Securities.
		

		
			If any mutilated Security is surrendered to the Trustee, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a new Security of the same 
		

		 

		

			10

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.
		

		
			If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction of the destruction, loss or theft of any Security and (ii) such security or indemnity bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to the Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and upon receipt of a Company Order the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.
		

		
			In case any such mutilated, destroyed, lost or stolen Security has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Security, pay such Security.
		

		
			Upon the issuance of any new Security under this Section, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.
		

		
			Every new Security of any Series issued pursuant to this Section in lieu of any destroyed, lost or stolen Security shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of that Series duly issued hereunder.
		

		
			The provisions of this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities.
		

		
			Section 2.9.   Outstanding Securities.
		

		
			The Securities outstanding at any time are all the Securities authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation, those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section as not outstanding.
		

		
			If a Security is replaced pursuant to Section 2.8, it ceases to be outstanding until the Trustee receives proof satisfactory to it that the replaced Security is held by a bona fide purchaser.
		

		
			If the Paying Agent (other than the Company, a Subsidiary of the Company or an Affiliate of the Company) holds on the Maturity of Securities of a Series money sufficient to pay such Securities payable on that date, then on and after that date such Securities of the Series cease to be outstanding and interest on them ceases to accrue.
		

		 

		

			11

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			The Company may purchase or otherwise acquire the Securities, whether by open market purchases, negotiated transactions or otherwise.  A Security does not cease to be outstanding because the Company or an Affiliate of the Company holds the Security (but see Section 2.10 below).
		

		
			In determining whether the Holders of the requisite principal amount of outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon a declaration of acceleration of the Maturity thereof pursuant to Section 6.2.
		

		
			Section 2.10.  Treasury Securities.
		

		
			In determining whether the Holders of the required principal amount of Securities of a Series have concurred in any request, demand, authorization, direction, notice, consent or waiver, Securities of a Series owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent or waiver only Securities of a Series that a Responsible Officer of the Trustee knows are so owned shall be so disregarded.
		

		
			Section 2.11.  Temporary Securities.
		

		
			Until definitive Securities are ready for delivery, the Company may prepare and the Trustee shall authenticate temporary Securities upon a Company Order.  Temporary Securities shall be substantially in the form of definitive Securities but may have variations that the Company considers appropriate for temporary Securities.  Without unreasonable delay, the Company shall prepare and the Trustee upon receipt of a Company Order shall authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities.  Until so exchanged, temporary securities shall have the same rights under this Indenture as the definitive Securities.
		

		
			Section 2.12.  Cancellation.
		

		
			The Company at any time may deliver Securities to the Trustee for cancellation.  The Registrar and the Paying Agent shall forward to the Trustee any Securities surrendered to them for registration of transfer, exchange or payment.  The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement or cancellation and shall destroy such canceled Securities (subject to the record retention requirement of the Exchange Act and the Trustee) and deliver a certificate of such cancellation to the Company upon written request of the Company.  The Company may not issue new Securities to replace Securities that it has paid or delivered to the Trustee for cancellation.
		

		
			Section 2.13.  Defaulted Interest.
		

		
			If the Company defaults in a payment of interest on a Series of Securities, it shall pay the defaulted interest, plus, to the extent permitted by law, any interest payable on the defaulted interest, to the persons who are Securityholders of the Series on a subsequent special record date.  
		

		 

		

			12

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			The Company shall fix the record date and payment date.  At least 10 days before the special record date, the Company shall send to the Trustee and to each Securityholder of the Series a notice that states the special record date, the payment date and the amount of interest to be paid.  The Company may pay defaulted interest in any other lawful manner.
		

		
			Section 2.14.  Global Securities.
		

		
			2.14.1.     Terms of Securities.  A Board Resolution, a supplemental indenture hereto or an Officer’s Certificate shall establish whether the Securities of a Series shall be issued in whole or in part in the form of one or more Global Securities and the Depositary for such Global Security or Securities.
		

		
			2.14.2.     Transfer and Exchange.  Notwithstanding any provisions to the contrary contained in Section 2.7 of the Indenture and in addition thereto, any Global Security shall be exchangeable pursuant to Section 2.7 of the Indenture for Securities registered in the names of Holders other than the Depositary for such Security or its nominee only if (i) such Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such Global Security or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in either case, the Company fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such event or (ii) the Company executes and delivers to the Trustee an Officer’s Certificate to the effect that such Global Security shall be so exchangeable.  Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered in such names as the Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the Global Security with like tenor and terms.
		

		
			Except as provided in this Section 2.14.2, a Global Security may not be transferred except as a whole by the Depositary with respect to such Global Security to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such a successor Depositary.
		

		
			2.14.3.     Legends.  Any Global Security issued hereunder shall bear a legend in substantially the following form:
		

		
			“THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY.  THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.”
		

		 

		

			13

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			In addition, so long as the Depository Trust Company (“DTC”) is the Depositary, each Global Note registered in the name of DTC or its nominee shall bear a legend in substantially the following form:
		

		
			“UNLESS THIS GLOBAL NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.”
		

		
			2.14.4.     Acts of Holders.  The Depositary, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture.
		

		
			2.14.5.     Payments.  Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.2, payment of the principal of and interest, if any, on any Global Security shall be made to the Holder thereof.
		

		
			2.14.6.     Consents, Declaration and Directions.  The Company, the Trustee and any Agent shall treat a person as the Holder of such principal amount of outstanding Securities of such Series represented by a Global Security as shall be specified in a written statement of the Depositary or by the applicable procedures of such Depositary with respect to such Global Security, for purposes of obtaining any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture.
		

		
			Section 2.15.  CUSIP Numbers.
		

		
			The Company in issuing the Securities may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers.
		

		
			Section 2.16.  Trustee Not Responsible for Securities Laws.
		

		
			Notwithstanding anything herein to the contrary, neither the Trustee nor the Registrar shall be responsible for ascertaining whether any transfer complies with the registration provisions of or exemptions from the Securities Acts of 1933, as amended, applicable state securities laws, or other applicable laws.
		

		

		

		 

		

			14

		

 

		

			Table of Contents

		

		

			 

		

		ARTICLE III.
REDEMPTION
		

		
			﻿
		

		
			Section 3.1.   Notice to Trustee.
		

		
			The Company may, with respect to any Series of Securities, reserve the right to redeem and pay the Series of Securities or may covenant to redeem and pay the Series of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities.  If a Series of Securities is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date, the redemption price and the principal amount of Series of Securities to be redeemed.  The Company shall give the notice at least 15 days before the redemption date, unless a shorter period is satisfactory to the Trustee.
		

		
			Section 3.2.   Selection of Securities to be Redeemed.
		

		
			Unless otherwise indicated for a particular Series by a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, if less than all the Securities of a Series are to be redeemed, the Securities of the Series to be redeemed will be selected as follows:  (a) if the Securities are in the form of Global Securities, in accordance with the procedures of the Depositary, (b) if the Securities are listed on any national securities exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed, or (c) if not otherwise provided for under clause (a) or (b) in the manner that the Trustee deems fair and appropriate, including by lot or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of Global Securities, to the applicable rules and procedures of the Depositary.  The Securities to be redeemed shall be selected from Securities of the Series outstanding not previously called for redemption.  Portions of the principal of Securities of the Series that have denominations larger than $1,000 may be selected for redemption.  Securities of the Series and portions of them it selected for redemption shall be in amounts of $1,000 or whole multiples of $1,000 or, with respect to Securities of any Series issuable in other denominations pursuant to Section 2.2.10, the minimum principal denomination for each Series and the authorized integral multiples thereof.  Provisions of this Indenture that apply to Securities of a Series called for redemption also apply to portions of Securities of that Series called for redemption.
		

		
			Section 3.3.   Notice of Redemption.
		

		
			Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, at least 15 days but not more than 60 days before a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance with the procedures of the Depositary, a notice of redemption to each Holder whose Securities are to be redeemed.
		

		
			The notice shall identify the Securities of the Series to be redeemed and shall state:
		

		
			(a)     the redemption date;
		

		 

		

			15

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(b)     the redemption price;
		

		
			(c)     the name and address of the Paying Agent;
		

		
			(d)     if any Securities are being redeemed in part, the portion of the principal amount of such Securities to be redeemed and that, after the redemption date and upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original Security shall be issued in the name of the Holder thereof upon cancellation of the original Security;
		

		
			(e)     that Securities of the Series called for redemption must be surrendered to the Paying Agent to collect the redemption price;
		

		
			(f)     that interest on Securities of the Series called for redemption ceases to accrue on and after the redemption date unless the Company defaults in the deposit of the redemption price;
		

		
			(g)     the CUSIP number, if any; and
		

		
			(h)     any other information as may be required by the terms of the particular Series or the Securities of a Series being redeemed.
		

		
			At the Company’s request, the Trustee shall give the notice of redemption in the Company’s name and at its expense, provided, however, that the Company has delivered to the Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer’s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice.  
		

		
			Section 3.4.   Effect of Notice of Redemption.
		

		
			Once notice of redemption is sent as provided in Section 3.3, Securities of a Series called for redemption become due and payable on the redemption date and at the redemption price.  Except as otherwise provided in the supplemental indenture, Board Resolution or Officer’s Certificate for a Series, a notice of redemption may not be conditional.  Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price plus accrued interest to the redemption date.
		

		
			Section 3.5.   Deposit of Redemption Price.
		

		
			On or before 11:00 a.m., New York City time, on the redemption date, the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date.
		

		
			Section 3.6.   Securities Redeemed in Part.
		

		
			Upon surrender of a Security that is redeemed in part, the Trustee shall authenticate for the Holder a new Security of the same Series and the same maturity equal in principal amount to the unredeemed portion of the Security surrendered.
		

		 

		

			16

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			ARTICLE IV.
COVENANTS
		

		
			﻿
		

		
			Section 4.1.   Payment of Principal and Interest.
		

		
			The Company covenants and agrees for the benefit of the Holders of each Series of Securities that it will duly and punctually pay the principal of and interest, if any, on the Securities of that Series in accordance with the terms of such Securities and this Indenture.  On or before 11:00 a.m., New York City time, on the applicable payment date, the Company shall deposit with the Paying Agent money sufficient to pay the principal of and interest, if any, on the Securities of each Series in accordance with the terms of such Securities and this Indenture.
		

		
			Section 4.2.   SEC Reports.
		

		
			To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee within 15 days after it files them with the SEC copies of the annual reports and of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act.  The Company also shall comply with the other provisions of TIA § 314(a). Reports, information and documents filed with the SEC via the EDGAR system will be deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section 4.2.
		

		
			Delivery of reports, information and documents to the Trustee under this Section 4.2 are for informational purposes only and the Trustee’s receipt of the foregoing shall not constitute constructive or actual notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of their covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer’s Certificates).
		

		
			Section 4.3.   Compliance Certificate.
		

		
			To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Company, an Officer’s Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made under the supervision of the signing Officers with a view to determining whether the Company has kept, observed, performed and fulfilled its obligations under this Indenture, and further stating, as to each such Officer signing such certificate, that to the best of his/her knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture and is not in default in the performance or observance of any of the terms, provisions and conditions hereof (or, if a Default or Event of Default shall have occurred, describing all such Defaults or Events of Default of which the Officer may have knowledge).
		

		
			Section 4.4.   Stay, Extension and Usury Laws.
		

		
			The Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which 
		

		 

		

			17

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			may affect the covenants or the performance of this Indenture or the Securities; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted.
		

		
			ARTICLE V.
SUCCESSORS
		

		
			﻿
		

		
			Section 5.1.   When Company May Merge, Etc.
		

		
			The Company shall not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of its properties and assets to, any person (a “successor person”) unless:
		

		
			(a)     the Company is the surviving corporation or the successor person (if other than the Company) is a corporation organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes the Company’s obligations on the Securities and under this Indenture; and
		

		
			(b)     immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.
		

		
			The Company shall deliver to the Trustee prior to the consummation of the proposed transaction an Officer’s Certificate to the foregoing effect and an Opinion of Counsel stating that the proposed transaction and any supplemental indenture comply with this Indenture.
		

		
			Notwithstanding the above, any Subsidiary of the Company may consolidate with, merge into or transfer all or part of its properties to the Company. Neither an Officer’s Certificate nor an Opinion of Counsel shall be required to be delivered in connection therewith.
		

		
			Section 5.2.   Successor Corporation Substituted.
		

		
			Upon any consolidation or merger, or any sale, lease, conveyance or other disposition of all or substantially all of the assets of the Company in accordance with Section 5.1, the successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease, conveyance or other disposition is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor person has been named as the Company herein; provided,  however, that the predecessor Company in the case of a sale, conveyance or other disposition (other than a lease) shall be released from all obligations and covenants under this Indenture and the Securities.
		

		 

		

			18

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			ARTICLE VI.
DEFAULTS AND REMEDIES
		

		
			﻿
		

		
			Section 6.1.   Events of Default.
		

		
			“Event of Default,” wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing Board Resolution, supplemental indenture or Officer’s Certificate, it is provided that such Series shall not have the benefit of said Event of Default:
		

		
			(a)     default in the payment of any interest on any Security of that Series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11:00 a.m., New  York City time, on the 30th day of such period); or
		

		
			(b)     default in the payment of principal of any Security of that Series at its Maturity; or
		

		
			(c)     default in the performance or breach of any covenant or warranty of the Company in this Indenture (other than defaults pursuant to paragraphs (a) or (b) above or pursuant to a covenant or warranty that has been included in this Indenture solely for the benefit of Series of Securities other than that Series), which default continues uncured for a period of 60 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the outstanding Securities of that Series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or
		

		
			(d)     the Company pursuant to or within the meaning of any Bankruptcy Law:
		

		
			(i)      commences a voluntary case,
		

		
			(ii)     consents to the entry of an order for relief against it in an involuntary case,
		

		
			(iii)    consents to the appointment of a Custodian of it or for all or substantially all of its property,
		

		
			(iv)     makes a general assignment for the benefit of its creditors, or
		

		
			(v)      generally is unable to pay its debts as the same become due; or
		

		
			(e)     a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that:
		

		
			(i)      is for relief against the Company in an involuntary case,
		

		 

		

			19

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(ii)     appoints a Custodian of the Company or for all or substantially all of its property, or
		

		
			(iii)    orders the liquidation of the Company,
		

		
			and the order or decree remains unstayed and in effect for 60 days; or
		

		
			(f)     any other Event of Default provided with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, in accordance with Section 2.2.18. 
		

		
			The term “Bankruptcy Law” means title 11, U.S. Code or any similar Federal or State law for the relief of debtors. The term “Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
		

		
			The Company will provide the Trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action the Company is taking or proposes to take in respect thereof.
		

		
			Section 6.2.   Acceleration of Maturity; Rescission and Annulment.
		

		
			If an Event of Default with respect to Securities of any Series at the time outstanding occurs and is continuing (other than an Event of Default referred to in Section 6.1(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities of that Series may declare the principal amount (or, if any Securities of that Series are Discount Securities, such portion of the principal amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that Series to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and payable.  If an Event of Default specified in Section 6.1(d) or (e) shall occur, the principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.
		

		
			At any time after such a declaration of acceleration with respect to any Series has been made and before a judgment or decree for payment of the money due has been obtained by the Trustee as hereinafter in this Article provided, the Holders of a majority in principal amount of the outstanding Securities of that Series, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if all Events of Default with respect to Securities of that Series, other than the non-payment of the principal and interest, if any, of Securities of that Series which have become due solely by such declaration of acceleration, have been cured or waived as provided in Section 6.13.
		

		
			No such rescission shall affect any subsequent Default or impair any right consequent thereon.
		

		 

		

			20

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 6.3.   Collection of Indebtedness and Suits for Enforcement by Trustee.
		

		
			The Company covenants that if
		

		
			(a)     default is made in the payment of any interest on any Security when such interest becomes due and payable and such default continues for a period of 30 days, or
		

		
			(b)     default is made in the payment of principal of any Security at the Maturity thereof, or
		

		
			(c)     default is made in the deposit of any sinking fund payment, if any, when and as due by the terms of a Security,
		

		
			then, the Company will, upon demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable on such Securities for principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue principal and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel.
		

		
			If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon such Securities and collect the moneys adjudged or deemed to be payable in the manner provided by law out of the property of the Company or any other obligor upon such Securities, wherever situated.
		

		
			If an Event of Default with respect to any Securities of any Series occurs and is continuing, the Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.
		

		
			Section 6.4.   Trustee May File Proofs of Claim.
		

		
			In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the Company or any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the Trustee (irrespective of whether the principal of the Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or interest) shall be entitled and empowered, by intervention in such proceeding or otherwise,
		

		
			(a)     to file and prove a claim for the whole amount of principal and interest owing and unpaid in respect of the Securities and to file such other papers or documents as 
		

		 

		

			21

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and
		

		
			(b)     to collect and receive any moneys or other property payable or deliverable on any such claims and to distribute the same,
		

		
			and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.7.
		

		
			Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.
		

		
			Section 6.5.   Trustee May Enforce Claims Without Possession of Securities.
		

		
			All rights of action and claims under this Indenture or the Securities may be prosecuted and enforced by the Trustee without the possession of any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such judgment has been recovered.
		

		
			Section 6.6.   Application of Money Collected.
		

		
			Any money or property collected by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such money or property on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment if only partially paid and upon surrender thereof if fully paid:
		

		
			First:       To the payment of all amounts due the Trustee under Section 7.7; and
		

		
			Second:   To the payment of the amounts then due and unpaid for principal of and interest on the Securities in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest, respectively; and
		

		
			Third:      To the Company.
		

		 

		

			22

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 6.7.   Limitation on Suits.
		

		
			No Holder of any Security of any Series shall have any right to institute any proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless
		

		
			(a)     such Holder has previously given written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series;
		

		
			(b)     the Holders of not less than 25% in principal amount of the outstanding Securities of that Series shall have made written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder;
		

		
			(c)     such Holder or Holders have offered to the Trustee indemnity or security satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by the Trustee in compliance with such request;
		

		
			(d)     the Trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and
		

		
			(e)     no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Securities of that Series;
		

		
			it being understood, intended and expressly covenanted by the Holder of every Security with every other Holder and the Trustee that no one or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.
		

		
			Section 6.8.   Unconditional Right of Holders to Receive Principal and Interest.
		

		
			Notwithstanding any other provision in this Indenture, the Holder of any Security shall have the right, which is absolute and unconditional, to receive payment of the principal of and interest, if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder.
		

		
			Section 6.9.   Restoration of Rights and Remedies.
		

		
			If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all 
		

		 

		

			23

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.
		

		
			Section 6.10.  Rights and Remedies Cumulative.
		

		
			Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in Section 2.8, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the extent permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.
		

		
			Section 6.11.  Delay or Omission Not Waiver.
		

		
			No delay or omission of the Trustee or of any Holder of any Securities to exercise any right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein.  Every right and remedy given by this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.
		

		
			Section 6.12.  Control by Holders.
		

		
			The Holders of a majority in principal amount of the outstanding Securities of any Series shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such Series, provided that
		

		
			(a)     such direction shall not be in conflict with any rule of law or with this Indenture,
		

		
			(b)     the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such direction, 
		

		
			(c)     subject to the provisions of Section 7.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability, and
		

		
			(d)     prior to taking any action as directed under this Section 6.12, the Trustee shall be entitled to indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.
		

		 

		

			24

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 6.13.  Waiver of Past Defaults.
		

		
			The Holders of not less than a majority in principal amount of the outstanding Securities of any Series may on behalf of the Holders of all the Securities of such Series, by written notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series and its consequences, except a Default in the payment of the principal of or interest on any Security of such Series (provided, however, that the Holders of a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration).  Upon any such waiver, such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or impair any right consequent thereon.
		

		
			Section 6.14.  Undertaking for Costs.
		

		
			All parties to this Indenture agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date).
		

		
			ARTICLE VII.
TRUSTEE
		

		
			﻿
		

		
			Section 7.1.   Duties of Trustee.
		

		
			(a)     If an Event of Default has occurred and is continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs.
		

		
			(b)     Except during the continuance of an Event of Default:
		

		
			(i)      The Trustee need perform only those duties that are specifically set forth in this Indenture and no others.
		

		
			(ii)     In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon Officer’s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture; however, in the case of any 
		

		 

		

			25

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			such Officer’s Certificates or Opinions of Counsel which by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall examine such Officer’s Certificates and Opinions of Counsel to determine whether or not they conform to the form requirements of this Indenture.
		

		
			(c)   The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful misconduct, except that:
		

		
			(i)      This paragraph does not limit the effect of paragraph (b) of this Section.
		

		
			(ii)     The Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts.
		

		
			(iii)    The Trustee shall not be liable with respect to any action taken, suffered or omitted to be taken by it with respect to Securities of any Series in good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series in accordance with Section 6.12.
		

		
			(d)     Every provision of this Indenture that in any way relates to the Trustee is subject to this Section and Section 7.2.
		

		
			(e)     The Trustee may refuse to perform any duty or exercise any right or power unless it receives indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in performing such duty or exercising such right or power.
		

		
			(f)     The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company.  Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law.
		

		
			(g)     No provision of this Indenture shall require the Trustee to risk its own funds or otherwise incur any financial liability in the performance of any of its duties, or in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee in its satisfaction.
		

		
			(h)     The Paying Agent, the Registrar and any authenticating agent shall be entitled to the protections and immunities as are set forth in paragraphs this Section and in Section 7.2, each with respect to the Trustee.
		

		
			Section 7.2.   Rights of Trustee.
		

		
			(a)     The Trustee may rely on and shall be protected in acting or refraining from acting upon any document (whether in its original or facsimile form) believed by it to be 
		

		 

		

			26

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			genuine and to have been signed or presented by the proper person.  The Trustee need not investigate any fact or matter stated in the document.
		

		
			(b)     Before the Trustee acts or refrains from acting, it may require an Officer’s Certificate or an Opinion of Counsel or both.  The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officer’s Certificate or Opinion of Counsel.
		

		
			(c)     The Trustee may act through agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care.  No Depositary shall be deemed an agent of the Trustee and the Trustee shall not be responsible for any act or omission by any Depositary.
		

		
			(d)     The Trustee shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers, provided that the Trustee’s conduct does not constitute willful misconduct or negligence.
		

		
			(e)     The Trustee may consult with counsel and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder without willful misconduct or negligence, and in reliance thereon.
		

		
			(f)     The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders of Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.
		

		
			(g)     The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit.
		

		
			(h)     The Trustee shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the Securities generally or the Securities of a particular Series and this Indenture.
		

		
			(i)     In no event shall the Trustee be liable to any person for special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage.
		

		
			(j)     The permissive right of the Trustee to take the actions permitted by this Indenture shall not be construed as an obligation or duty to do so.
		

		 

		

			27

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(k)     The Trustee is not responsible for monitoring the performance of other persons or for the failure of others to perform their duties. 
		

		
			(l)     Any action taken, or omitted to be taken, by the Trustee in good faith pursuant to this Indenture upon the request or authority or consent of any person who, at the time of making such request or giving such authority or consent, is the holder of any Note shall be conclusive and binding upon future holders of Notes, and upon Notes executed and delivered in exchange therefor or in place thereof.
		

		
			(m)     The Trustee may request that the Issuer deliver an Officer’s Certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture, which Officer’s Certificate may be signed by any Person authorized to sign an Officer’s Certificate, including any Person specified as so authorized in any such certificate previously delivered and not superseded. 
		

		
			(n)     The Trustee shall not be required to give any bond or surety in respect of the execution of the trusts and powers under this Indenture.
		

		
			Section 7.3.   Individual Rights of Trustee.
		

		
			The Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee.  Any Agent may do the same with like rights.  The Trustee is also subject to Sections 7.10 and 7.11.
		

		
			Section 7.4.   Trustee’s Disclaimer.
		

		
			The Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities, it shall not be accountable for the Company’s use of the proceeds from the Securities, and it shall not be responsible for any statement in the Securities other than its authentication.
		

		
			Section 7.5.   Notice of Defaults.
		

		
			If a Default or Event of Default occurs and is continuing with respect to the Securities of any Series and if it is actually known to a Responsible Officer of the Trustee, the Trustee shall send to each Securityholder of the Securities of that Series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a Responsible Officer of the Trustee has actual knowledge of such Default or Event of Default.  Except in the case of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice if and so long as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Securityholders of that Series.
		

		
			Section 7.6.   Reports by Trustee to Holders.
		

		
			Within 60 days after each [   ] commencing [   ], [   ], the Trustee shall transmit by mail to all Securityholders, as their names and addresses appear on the register kept by the 
		

		 

		

			28

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Registrar, a brief report dated as of such anniversary date, in accordance with, and to the extent required under, TIA § 313.
		

		
			A copy of each report at the time of its mailing to Securityholders of any Series shall be filed with the SEC and each national securities exchange on which the Securities of that Series are listed.  The Company shall promptly notify the Trustee in writing when Securities of any Series are listed on any national securities exchange.
		

		
			Section 7.7.   Compensation and Indemnity.
		

		
			The Company shall pay to the Trustee from time to time compensation for its services as the Company and the Trustee shall from time to time agree upon in writing.  The Trustee’s compensation shall not be limited by any law on compensation of a trustee of an express trust.  The Company shall reimburse the Trustee upon request for all reasonable out of pocket expenses incurred by it.  Such expenses shall include the reasonable compensation and expenses of the Trustee’s agents and counsel.
		

		
			The Company shall indemnify and hold harmless each of the Trustee and any predecessor Trustee (including for the cost of defending itself or enforcing this indemnity) against any cost, expense or liability, including taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred by it as Trustee or Agent under this Indenture except as set forth in the next paragraph in the performance of its duties under this Indenture as Trustee or Agent.  The Trustee shall notify the Company promptly of any third party claim for which it may seek indemnity.  Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder, unless and to the extent that the Company is materially prejudiced thereby.  The Company shall defend any third party claim and the Trustee shall cooperate in the defense.  The Trustee may have one separate counsel plus local counsel, if applicable, and the Company shall pay the reasonable fees and expenses of such counsel.  The Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld.  This indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee.
		

		
			The Company need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director, employee, shareholder or agent of the Trustee through willful misconduct or negligence.  
		

		
			To secure the Company’s payment obligations in this Section, the Trustee shall have a lien prior to the Securities of any Series on all money or property held or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.
		

		
			When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.1(d) or (e) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law.
		

		
			The provisions of this Section shall survive the termination of this Indenture and the resignation or removal of the Trustee.
		

		 

		

			29

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 7.8.   Replacement of Trustee.
		

		
			A resignation or removal of the Trustee and appointment of a successor Trustee shall become effective only upon the successor Trustee’s acceptance of appointment as provided in this Section.
		

		
			The Trustee may resign with respect to the Securities of one or more Series by so notifying the Company at least 30 days prior to the date of the proposed resignation.  The Holders of a majority in principal amount of the Securities of any Series may remove the Trustee with respect to that Series by so notifying the Trustee and the Company.  The Company may remove the Trustee with respect to Securities of one or more Series if:
		

		
			(a)     the Trustee fails to comply with Section 7.10;
		

		
			(b)     the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;
		

		
			(c)     a Custodian or public officer takes charge of the Trustee or its property; or
		

		
			(d)     the Trustee becomes incapable of acting.
		

		
			If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee.  Within one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee to replace the successor Trustee appointed by the Company.
		

		
			If a successor Trustee with respect to the Securities of any one or more Series does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series may petition any court of competent jurisdiction for the appointment of a successor Trustee.
		

		
			A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company.  Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section 7.7, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture.  A successor Trustee shall mail a notice of its succession to each Securityholder of each such Series.  Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Company’s obligations under Section 7.7 hereof shall continue for the benefit of the retiring Trustee with respect to expenses and liabilities incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture prior to such replacement.
		

		 

		

			30

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 7.9.   Successor Trustee by Merger, Etc.
		

		
			If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust business to, another corporation, the successor corporation without any further act shall be the successor Trustee, subject to Section 7.10.
		

		
			Section 7.10.  Eligibility; Disqualification.
		

		
			This Indenture shall always have a Trustee who satisfies the requirements of TIA § 310(a)(1), (2) and (5).  The Trustee shall always have a combined capital and surplus of at least $25,000,000 as set forth in its most recent published annual report of condition.  The Trustee shall comply with TIA § 310(b).
		

		
			Section 7.11.  Preferential Collection of Claims Against Company.
		

		
			The Trustee is subject to TIA § 311(a), excluding any creditor relationship listed in TIA § 311(b).  A Trustee who has resigned or been removed shall be subject to TIA § 311(a) to the extent indicated.
		

		
			ARTICLE VIII.
SATISFACTION AND DISCHARGE; DEFEASANCE
		

		
			﻿
		

		
			Section 8.1.   Satisfaction and Discharge of Indenture.
		

		
			This Indenture shall upon Company Order be discharged with respect to the Securities of any Series and cease to be of further effect as to all Securities of such Series (except as hereinafter provided in this Section 8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging satisfaction and discharge of this Indenture, when
		

		
			(a)     either
		

		
			(i)      all Securities of such Series theretofore authenticated and delivered (other than Securities that have been destroyed, lost or stolen and that have been replaced or paid) have been delivered to the Trustee for cancellation; or
		

		
			(ii)     all such Securities of such Series not theretofore delivered to the Trustee for cancellation
		

		
			(1)     have become due and payable by reason of sending a notice of redemption or otherwise, or
		

		
			(2)     will become due and payable at their Stated Maturity within one year, or
		

		
			(3)     have been called for redemption or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company, or
		

		 

		

			31

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(4)     are deemed paid and discharged pursuant to Section 8.3, as applicable;
		

		
			and the Company, in the case of (1), (2) or (3) above, shall have irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust an amount of money or U.S. Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due;
		

		
			(b)     the Company has paid or caused to be paid all other sums payable hereunder by the Company; and
		

		
			(c)      the Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the satisfaction and discharge contemplated by this Section have been complied with.
		

		
			Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.7, and, if money shall have been deposited with the Trustee pursuant to clause (a) of this Section, the provisions of Sections 2.4, 2.7, 2.8, 8.2 and  8.5 shall survive.
		

		
			Section 8.2.   Application of Trust Funds; Indemnification.
		

		
			(a)     Subject to the provisions of Section 8.5, all money and U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated by Sections 8.1, 8.3 or 8.4.
		

		
			(b)     The Company shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on or assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Sections 8.1, 8.3 or 8.4 or the interest and principal received in respect of such obligations other than any payable by or on behalf of Holders.
		

		
			(c)     The Trustee shall deliver or pay to the Company from time to time upon Company Order any U.S. Government Obligations or Foreign Government Obligations or money held by it as provided in Sections 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government Obligations or money were 
		

		 

		

			32

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			deposited or received.  This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or Foreign Government Obligations held under this Indenture.
		

		
			Section 8.3.   Legal Defeasance of Securities of any Series.
		

		
			Unless this Section 8.3 is otherwise specified, pursuant to Section 2.2, to be inapplicable to Securities of any Series, the Company shall be deemed to have paid and discharged the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph (d) hereof, and the provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall no longer be in effect (and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments acknowledging the same), except as to:
		

		
			(a)     the rights of Holders of Securities of such Series to receive, from the trust funds described in subparagraph (d) hereof, (i) payment of the principal of and each installment of principal of and interest on the outstanding Securities of such Series on the Maturity of such principal or installment of principal or interest and (ii) the benefit of any mandatory sinking fund payments applicable to the Securities of such Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series;
		

		
			(b)     the provisions of Sections 2.4, 2.5, 2.7, 2.8, 7.7, 8.2, 8.3, 8.5 and 8.6; and
		

		
			(c)     the rights, powers, trusts and immunities of the Trustee hereunder and the Company’s obligations in connection therewith;
		

		
			provided that, the following conditions shall have been satisfied:
		

		
			(d)     the Company shall have irrevocably deposited or caused to be deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds specifically pledged as security for and dedicated solely to the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal of and interest, on and any mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of principal or interest and such sinking fund payments are due;
		

		
			(e)     such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is a party or by which it is bound;
		

		 

		

			33

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(f)     no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit or during the period ending on the 91st day after such date;
		

		
			(g)     the Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel to the effect that (i) the Company has received from, or there has been published by, the Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there has been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit, defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred;
		

		
			(h)     the Company shall have delivered to the Trustee an Officer’s Certificate stating that the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and
		

		
			(i)     the Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the defeasance contemplated by this Section have been complied with.
		

		
			Section 8.4.   Covenant Defeasance.
		

		
			Unless this Section 8.4 is otherwise specified pursuant to Section 2.2 to be inapplicable to Securities of any Series, the Company may omit to comply with respect to the Securities of any Series with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified therein, any additional covenants specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer’s Certificate delivered pursuant to Section 2.2 (and the failure to comply with any such covenants shall not constitute a Default or Event of Default with respect to such Series under Section 6.1) and the occurrence of any event specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer’s Certificate delivered pursuant to Section 2.2 and designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, but, except as specified above, the remainder of this Indenture and such Securities will be unaffected thereby; provided that the following conditions shall have been satisfied:
		

		
			(a)     with reference to this Section 8.4, the Company has irrevocably deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect 
		

		 

		

			34

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due;
		

		
			(b)     such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is a party or by which it is bound;
		

		
			(c)     no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit;
		

		
			(d)     the Company shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel to the effect that (i) the company has received from, or there has been published by, the Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there has been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm, subject to customary exclusions, that the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit, covenant defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit, covenant defeasance and discharge had not occurred;
		

		
			(e)     The Company shall have delivered to the Trustee an Officer’s Certificate stating the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and
		

		
			(f)     The Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the covenant defeasance contemplated by this Section have been complied with.
		

		
			Section 8.5.   Repayment to Company.
		

		
			Subject to applicable abandoned property law, the Trustee and the Paying Agent shall pay to the Company upon request any money held by them for the payment of principal and interest that remains unclaimed for two years.  After that, Securityholders entitled to the money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another person.
		

		
			Section 8.6.   Reinstatement.
		

		
			If the Trustee or the Paying Agent is unable to apply any money deposited with respect to Securities of any Series in accordance with Section 8.1 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining 
		

		 

		

			35

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			or otherwise prohibiting such application, the obligations of the Company under this Indenture with respect to the Securities of such Series and under the Securities of such Series shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1 until such time as the Trustee or the Paying Agent is permitted to apply all such money in accordance with Section 8.1; provided,  however, that if the Company has made any payment of principal of or interest on any Securities because of the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or U.S. Government Obligations held by the Trustee or Paying Agent after payment in full to the Holders.
		

		
			ARTICLE IX.
AMENDMENTS AND WAIVERS
		

		
			﻿
		

		
			Section 9.1.   Without Consent of Holders.
		

		
			The Company and the Trustee may amend or supplement this Indenture or the Securities of one or more Series without the consent of any Securityholder:
		

		
			(a)     to cure any ambiguity, defect or inconsistency;
		

		
			(b)     to comply with Article V;
		

		
			(c)     to provide for uncertificated Securities in addition to or in place of certificated Securities;
		

		
			(d)     to add guarantees with respect to Securities of any Series or secure Securities of any Series;
		

		
			(e)     to surrender any of the Company’s rights or powers under this Indenture;
		

		
			(f)     to add covenants or events of default for the benefit of the holders of Securities of any Series;
		

		
			(g)     to comply with the applicable procedures of the applicable depositary;
		

		
			(h)     to make any change that does not adversely affect the rights of any Securityholder;
		

		
			(i)     to provide for the issuance of and establish the form and terms and conditions of Securities of any Series as permitted by this Indenture;
		

		
			(j)     to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee; or
		

		
			(k)     to comply with requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA.
		

		 

		

			36

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 9.2.   With Consent of Holders.
		

		
			The Company and the Trustee may enter into a supplemental indenture with the written consent of the Holders of at least a majority in principal amount of the outstanding Securities of each Series affected by such supplemental indenture (including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series), for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the Securityholders of each such Series.  Except as provided in Section 6.13, the Holders of at least a majority in principal amount of the outstanding Securities of any Series by notice to the Trustee (including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series) may waive compliance by the Company with any provision of this Indenture or the Securities with respect to such Series.
		

		
			It shall not be necessary for the consent of the Holders of Securities under this Section 9.2 to approve the particular form of any proposed supplemental indenture or waiver, but it shall be sufficient if such consent approves the substance thereof.  After a supplemental indenture or waiver under this section becomes effective, the Company shall send to the Holders of Securities affected thereby, a notice briefly describing the supplemental indenture or waiver.  Any failure by the Company to send such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture or waiver.
		

		
			Section 9.3.   Limitations.
		

		
			Without the consent of each Securityholder affected, an amendment or waiver may not:
		

		
			(a)     reduce the principal amount of Securities whose Holders must consent to an amendment, supplement or waiver;
		

		
			(b)     reduce the rate of or extend the time for payment of interest (including default interest) on any Security;
		

		
			(c)     reduce the principal or change the Stated Maturity of any Security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation;
		

		
			(d)     reduce the principal amount of Discount Securities payable upon acceleration of the maturity thereof;
		

		
			(e)     waive a Default or Event of Default in the payment of the principal of or interest, if any, on any Security (except a rescission of acceleration of the Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities of such Series and a waiver of the payment default that resulted from such acceleration);
		

		
			(f)     make the principal of or interest, if any, on any Security payable in any currency other than that stated in the Security;
		

		 

		

			37

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(g)     make any change in Sections 6.8, 6.13 or 9.3 (this sentence); or
		

		
			(h)     waive a redemption payment with respect to any Security, provided that such redemption is made at the Company’s option.
		

		
			Section 9.4.   Compliance with Trust Indenture Act.
		

		
			Every amendment to this Indenture or the Securities of one or more Series shall be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.
		

		
			Section 9.5.   Revocation and Effect of Consents.
		

		
			Until an amendment is set forth in a supplemental indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security, even if notation of the consent is not made on any Security.  However, any such Holder or subsequent Holder may revoke the consent as to his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the date the waiver becomes effective.
		

		
			Any amendment or waiver once effective shall bind every Securityholder of each Series affected by such amendment or waiver unless it is of the type described in any of clauses (a) through (h) of Section 9.3.  In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security.
		

		
			The Company may, but shall not be obligated to, fix a record date for the purpose of determining the Holders entitled to give their consent or take any other action described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the second immediately preceding paragraph, those Persons who were Holders at such record date (or their duly designated proxies), and only those persons, shall be entitled to give such consent or to revoke any consent previously given or take any such action, whether or not such Persons continue to be Holders after such record date. No such consent shall be valid or effective for more than 120 days after such record date.
		

		
			Section 9.6.   Notation on or Exchange of Securities.
		

		
			The Company or the Trustee may place an appropriate notation about an amendment or waiver on any Security of any Series thereafter authenticated.  The Company in exchange for Securities of that Series may issue and the Trustee shall authenticate upon receipt of a Company Order in accordance with Section 2.3 new Securities of that Series that reflect the amendment or waiver.
		

		
			Section 9.7.   Trustee Protected.
		

		
			In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully 
		

		 

		

			38

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			protected in relying upon, an Officer’s Certificate or an Opinion of Counsel or both complying with Section 10.4.  The Trustee shall sign all supplemental indentures upon delivery of such an Officer’s Certificate or Opinion of Counsel or both, except that the Trustee need not sign any supplemental indenture that adversely affects its rights, duties, liabilities or immunities under this Indenture.
		

		
			ARTICLE X.
MISCELLANEOUS
		

		
			﻿
		

		
			Section 10.1.  Trust Indenture Act Controls.
		

		
			If any provision of this Indenture limits, qualifies, or conflicts with another provision which is required or deemed to be included in this Indenture by the TIA, such required or deemed provision shall control.
		

		
			Section 10.2.  Notices.
		

		
			Any notice or communication by the Company or the Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in writing and delivered in person or mailed by first‐class mail (registered or certified, return receipt requested), facsimile transmission, email or overnight air courier guaranteeing next day delivery, to the others’ address:
		

		
			if to the Company:
		

		
			﻿
		

		
			Aratana Therapeutics, Inc.
		

		
			11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 
		

		
			(913)-353-1000
		

		
			Attention: General Counsel
		

		
			﻿
		

		
			with a copy to:
		

		
			﻿
		

		
			Latham & Watkins LLP
		

		
			Attention: Peter N. Handrinos, Esq.
		

		
			200 Clarendon Street, 27th Floor
		

		
			Boston, MA 02116
		

		
			(617) 948-6000
		

		
			﻿
		

		
			if to the Trustee:
		

		
			﻿
		

		
			Wilmington Trust, National Association
		

		
			Global Capital Markets
		

		
			50 South Street, Suite 1290
		

		
			Minneapolis, Minnesota 55402
		

		
			Attention: Aratana Therapeutics Administrator
		

		
			Telephone: (612) 217-5651
		

		
			﻿
		

		
			The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.
		

		 

		

			39

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Any notice or communication to a Securityholder shall be sent electronically or by first-class mail to his, her or its address shown on the register kept by the Registrar, in accordance with the procedures of the Depositary.  Failure to send a notice or communication to a Securityholder of any Series or any defect in it shall not affect its sufficiency with respect to other Securityholders of that or any other Series.
		

		
			If a notice or communication is sent or published in the manner provided above, within the time prescribed, it is duly given, whether or not the Securityholder receives it.
		

		
			If the Company sends a notice or communication to Securityholders, it shall send a copy to the Trustee and each Agent at the same time.
		

		
			Notwithstanding any other provision of this Indenture or any Security, where this Indenture or any Security provides for notice of any event (including any notice of redemption) to a Holder of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security (or its designee) pursuant to the customary procedures of such Depositary. 
		

		
			Section 10.3.  Communication by Holders with Other Holders.
		

		
			Securityholders of any Series may communicate pursuant to TIA § 312(b) with other Securityholders of that Series or any other Series with respect to their rights under this Indenture or the Securities of that Series or all Series.  The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA § 312(c).
		

		
			Section 10.4.  Certificate and Opinion as to Conditions Precedent.
		

		
			Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee:
		

		
			(a)     an Officer’s Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and
		

		
			(b)     an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.
		

		
			Section 10.5.  Statements Required in Certificate or Opinion.
		

		
			Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to TIA § 314(a)(4)) shall comply with the provisions of TIA § 314(e) and shall include:
		

		
			(a)     a statement that the person making such certificate or opinion has read such covenant or condition;
		

		 

		

			40

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			(b)     a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;
		

		
			(c)     a statement that, in the opinion of such person, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and
		

		
			(d)     a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.
		

		
			Section 10.6.  Rules by Trustee and Agents.
		

		
			The Trustee may make reasonable rules for action by or a meeting of Securityholders of one or more Series.  Any Agent may make reasonable rules and set reasonable requirements for its functions.
		

		
			Section 10.7.  Legal Holidays.
		

		
			A “Legal Holiday” is any day that is not a Business Day.  If a payment date is a Legal Holiday at a place of payment, payment may be made at that place on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period.
		

		
			Section 10.8.  No Recourse Against Others.
		

		
			A director, officer, employee or stockholder (past or present), as such, of the Company shall not have any liability for any obligations of the Company under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation.  Each Securityholder by accepting a Security waives and releases all such liability.  The waiver and release are part of the consideration for the issue of the Securities.
		

		
			Section 10.9.  Counterparts.
		

		
			This Indenture may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.
		

		
			Section 10.10. Governing Law; Waiver of Jury Trial; Consent to Jurisdiction.
		

		
			THIS INDENTURE AND THE SECURITIES, INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.
		

		 

		

			41

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			THE COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR ACCEPTANCE OF THE SECURITIES) EACH HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.
		

		
			Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the non exclusive jurisdiction of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The Company, the Trustee and the Holders (by their acceptance of the Securities) each hereby irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.
		

		
			Section 10.11. No Adverse Interpretation of Other Agreements.
		

		
			This Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary of the Company.  Any such indenture, loan or debt agreement may not be used to interpret this Indenture.
		

		
			Section 10.12. Successors.
		

		
			All agreements of the Company in this Indenture and the Securities shall bind its successor.  All agreements of the Trustee in this Indenture shall bind its successor.
		

		
			Section 10.13. Severability.
		

		
			In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
		

		
			Section 10.14. Table of Contents, Headings, Etc.
		

		
			The Table of Contents, Cross Reference Table, and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.
		

		
			Section 10.15. Securities in a Foreign Currency.
		

		
			Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a 
		

		 

		

			42

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in more than one currency, then the principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be determined by converting any such other currency into a currency that is designated upon issuance of any particular Series of Securities.  Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, such conversion shall be at the spot rate for the purchase of the designated currency as published in The Financial Times in the “Currency Rates” section (or, if The Financial Times is no longer published, or if such information is no longer available in The Financial Times, such source as may be selected in good faith by the Company) on any date of determination.  The provisions of this paragraph shall apply in determining the equivalent principal amount in respect of Securities of a Series denominated in currency other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.
		

		
			All decisions and determinations provided for in the preceding paragraph shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all purposes and irrevocably binding upon the Trustee and all Holders.
		

		
			Section 10.16. Judgment Currency.
		

		
			The Company agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if for the purpose of obtaining judgment in any court it is necessary to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the “Required Currency”) into a currency in which a judgment will be rendered (the “Judgment Currency”), the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the day on which final unappealable judgment is entered, unless such day is not a New York Banking Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any currency other than the Required Currency, except to the extent that such tender or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture.  For purposes of the foregoing, “New York Banking Day” means any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions are authorized or required by law, regulation or executive order to close.
		

		 

		

			43

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			Section 10.17. Force Majeure.
		

		
			In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 
		

		
			Section 10.18. U.S.A. Patriot Act.
		

		
			The parties hereto acknowledge that in accordance with Section 326 of the U.S.A. Patriot Act, the Trustee is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee.  The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. Patriot Act.
		

		
			ARTICLE XI.
SINKING FUNDS
		

		
			﻿
		

		
			Section 11.1.  Applicability of Article.
		

		
			The provisions of this Article shall be applicable to any sinking fund for the retirement of the Securities of a Series if so provided by the terms of such Securities pursuant to  Section 2.2 and except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture.
		

		
			The minimum amount of any sinking fund payment provided for by the terms of the Securities of any Series is herein referred to as a “mandatory sinking fund payment” and any other amount provided for by the terms of Securities of such Series is herein referred to as an “optional sinking fund payment.”  If provided for by the terms of Securities of any Series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 11.2.  Each sinking fund payment shall be applied to the redemption of Securities of any Series as provided for by the terms of the Securities of such Series.
		

		
			Section 11.2.  Satisfaction of Sinking Fund Payments with Securities.
		

		
			The Company may, in satisfaction of all or any part of any sinking fund payment with respect to the Securities of any Series to be made pursuant to the terms of such Securities (1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities previously called for mandatory sinking fund redemption) and (2) apply as credit Securities of such Series to which such sinking fund payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company pursuant to the terms of such Series of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been 
		

		 

		

			44

		

 

		

			Table of Contents

		

		

			 

		

		
		

		
			previously so credited.  Such Securities shall be received by the Trustee, together with an Officer’s Certificate with respect thereto, not later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for redemption, and shall be credited for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly.  If as a result of the delivery or credit of Securities in lieu of cash payments pursuant to this Section 11.2, the principal amount of Securities of such Series to be redeemed in order to exhaust the aforesaid cash payment shall be less than $100,000, the Trustee need not call Securities of such Series for redemption, except upon receipt of a Company Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent and applied to the next succeeding sinking fund payment, provided,  however, that the Trustee or such Paying Agent shall from time to time upon receipt of a Company Order pay over and deliver to the Company any cash payment so being held by the Trustee or such Paying Agent upon delivery by the Company to the Trustee of Securities of that Series purchased by the Company having an unpaid principal amount equal to the cash payment required to be released to the Company.
		

		
			Section 11.3.  Redemption of Securities for Sinking Fund.
		

		
			Not less than 45 days (unless otherwise indicated in the Board Resolution, supplemental indenture hereto or Officer’s Certificate in respect of a particular Series of Securities) prior to each sinking fund payment date for any Series of Securities, the Company will deliver to the Trustee an Officer’s Certificate specifying the amount of the next ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by delivering and crediting of Securities of that Series pursuant to Section 11.2, and the optional amount, if any, to be added in cash to the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay the amount therein specified.  Not less than 30 days (unless otherwise indicated in the Board Resolution, Officer’s Certificate or supplemental indenture in respect of a particular Series of Securities) before each such sinking fund payment date the Securities to be redeemed upon such sinking fund payment date will be selected in the manner specified in Section 3.2 and the Company shall send or cause to be sent a notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in and in accordance with Section 3.3.  Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Sections 3.4, 3.5 and 3.6.
		

		
			﻿
		

		
			 
		

		

		

		 

		

			45

		

 

		

			Table of Contents

		

		

			 

		

		IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the day and year first above written.
		

		
			﻿
		

			
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						Aratana Therapeutics, Inc.

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						By:

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						Name:

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						Its:

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						Wilmington Trust, National Association,

					
					
						 

				
	
					
						﻿

					
					
						as Trustee

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						By:

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						Name:

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						Its:

					
					
						 

				

		
			﻿
		

		
			﻿EX10-2

		
			Exhibit 10.2
		

		
			GENOMIC HEALTH, INC.
		

		
			AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN
		

		
			(As amended on January 31, 2017)
		

		
			 
		

		
			 
		

		
			

		 

 

		

			 

		

		

		
			Table of Contents
		

		
			Page
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						SECTION 1.

					
					
						   

					
					
						ESTABLISHMENT AND PURPOSE.

					
					
						1

				
	
					
						SECTION 2.

					
					
						 

					
					
						DEFINITIONS.

					
					
						1

				
	
					
						(a)

					
					
						 

					
					
						“Affiliate”

					
					
						1

				
	
					
						(b)

					
					
						 

					
					
						“Award”

					
					
						1

				
	
					
						(c)

					
					
						 

					
					
						“Board of Directors”

					
					
						1

				
	
					
						(d)

					
					
						 

					
					
						“Change in Control”

					
					
						1

				
	
					
						(e)

					
					
						 

					
					
						“Code”

					
					
						2

				
	
					
						(f)

					
					
						 

					
					
						“Committee”

					
					
						2

				
	
					
						(g)

					
					
						 

					
					
						“Company”

					
					
						2

				
	
					
						(h)

					
					
						 

					
					
						“Consultant”

					
					
						3

				
	
					
						(i)

					
					
						 

					
					
						“Employee”

					
					
						3

				
	
					
						(j)

					
					
						 

					
					
						“Exchange Act”

					
					
						3

				
	
					
						(k)

					
					
						 

					
					
						“Exercise Price”

					
					
						3

				
	
					
						(l)

					
					
						 

					
					
						“Fair Market Value”

					
					
						3

				
	
					
						(m)

					
					
						 

					
					
						“ISO”

					
					
						3

				
	
					
						(n)

					
					
						 

					
					
						“Nonstatutory Option” or “NSO”

					
					
						3

				
	
					
						(o)

					
					
						 

					
					
						“Offeree”

					
					
						4

				
	
					
						(p)

					
					
						 

					
					
						“Option”

					
					
						4

				
	
					
						(q)

					
					
						 

					
					
						“Optionee”

					
					
						4

				
	
					
						(r)

					
					
						 

					
					
						“Outside Director”

					
4
				
	
					
						(s)

					
					
						 

					
					
						“Parent”

					
4
				
	
					
						(t)

					
					
						 

					
					
						“Participant”

					
4
				
	
					
						(u)

					
					
						 

					
					
						“Plan”

					
4
				
	
					
						(v)

					
					
						 

					
					
						“Purchase Price”

					
					
						4

				
	
					
						(w)

					
					
						 

					
					
						“Restricted Share”

					
					
						4

				
	
					
						(x)

					
					
						 

					
					
						“Restricted Share Agreement”

					
					
						4

				
	
					
						(y)

					
					
						 

					
					
						“SAR”

					
					
						4

				
	
					
						(z)

					
					
						 

					
					
						“SAR Agreement”

					
					
						4

				
	
					
						(aa)

					
					
						 

					
					
						“Service”

					
					
						4

				
	
					
						(bb)

					
					
						 

					
					
						“Share”

					
					
						5

				
	
					
						(cc)

					
					
						 

					
					
						“Stock”

					
					
						5

				
	
					
						(dd)

					
					
						 

					
					
						“Stock Option Agreement”

					
					
						5

				
	
					
						(ee)

					
					
						 

					
					
						“Stock Unit”

					
					
						5

				
	
					
						(ff)

					
					
						 

					
					
						“Stock Unit Agreement”

					
					
						5

				
	
					
						(gg)

					
					
						 

					
					
						“Subsidiary”

					
					
						5

				
	
					
						(hh)

					
					
						 

					
					
						“Total and Permanent Disability”

					
					
						5

				
	
					
						SECTION 3.

					
					
						 

					
					
						ADMINISTRATION.

					
					
						5

				
	
					
						(a)

					
					
						 

					
					
						Committee Composition

					
					
						5

				
	
					
						(b)

					
					
						 

					
					
						Committee for Non-Officer Grants

					
					
						5

				
	
					
						(c)

					
					
						 

					
					
						Committee Procedures

					
					
						6

				
	
					
						(d)

					
					
						 

					
					
						Committee Responsibilities

					
					
						6

				
	
					
						SECTION 4.

					
					
						 

					
					
						ELIGIBILITY.

					
					
						7

				
	
					
						(a)

					
					
						 

					
					
						General Rule

					
					
						7

				
	
					
						(b)

					
					
						 

					
					
						Automatic Grants to Outside Directors

					
					
						7

				
	
					
						(c)

					
					
						 

					
					
						Ten-Percent Stockholders

					
					
						8

				
	
					
						(d)

					
					
						 

					
					
						Attribution Rules

					
					
						8

				
	
					
						(e)

					
					
						 

					
					
						Outstanding Stock

					
					
						8

				
	
					
						SECTION 5.

					
					
						 

					
					
						STOCK SUBJECT TO PLAN.

					
					
						9

				
	
					
						(a)

					
					
						 

					
					
						Basic Limitation

					
					
						9

				
	
					
						(b)

					
					
						 

					
					
						Award Limitation

					
					
						9

				
	
					
						(c)

					
					
						 

					
					
						Additional Shares

					
					
						9

				

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  i  -

		

 

		

			 

		

	
					
						

					
						SECTION 6.

					
					
						 

					
					
						RESTRICTED SHARES.

					
					
						9

				
	
					
						(a)

					
					
						 

					
					
						Restricted Stock Agreement

					
					
						9

				
	
					
						(b)

					
					
						 

					
					
						Payment for Awards

					
					
						9

				
	
					
						(c)

					
					
						 

					
					
						Vesting

					
					
						10

				
	
					
						(d)

					
					
						 

					
					
						Voting and Dividend Rights

					
					
						10

				
	
					
						(e)

					
					
						 

					
					
						Restrictions on Transfer of Shares

					
					
						10

				
	
					
						SECTION 7.

					
					
						 

					
					
						TERMS AND CONDITIONS OF OPTIONS.

					
					
						10

				
	
					
						(a)

					
					
						 

					
					
						Stock Option Agreement

					
					
						10

				
	
					
						(b)

					
					
						 

					
					
						Number of Shares

					
					
						10

				
	
					
						(c)

					
					
						 

					
					
						Exercise Price

					
					
						10

				
	
					
						(d)

					
					
						 

					
					
						Withholding Taxes

					
					
						11

				
	
					
						(e)

					
					
						 

					
					
						Exercisability and Term

					
					
						11

				
	
					
						(f)

					
					
						 

					
					
						Exercise of Options

					
					
						11

				
	
					
						(g)

					
					
						 

					
					
						Effect of Change in Control

					
					
						11

				
	
					
						(h)

					
					
						 

					
					
						No Rights as a Stockholder

					
					
						11

				
	
					
						(i)

					
					
						 

					
					
						Modification, Extension and Renewal of Options

					
					
						11

				
	
					
						(j)

					
					
						 

					
					
						Restrictions on Transfer of Shares

					
					
						12

				
	
					
						(k)

					
					
						 

					
					
						Buyout Provisions

					
					
						12

				
	
					
						SECTION 8.

					
					
						 

					
					
						PAYMENT FOR SHARES.

					
					
						12

				
	
					
						(a)

					
					
						 

					
					
						General Rule

					
					
						12

				
	
					
						(b)

					
					
						 

					
					
						Surrender of Stock

					
					
						12

				
	
					
						(c)

					
					
						 

					
					
						Services Rendered

					
					
						12

				
	
					
						(d)

					
					
						 

					
					
						Cashless Exercise

					
					
						12

				
	
					
						(e)

					
					
						 

					
					
						Exercise/Pledge

					
					
						12

				
	
					
						(f)

					
					
						 

					
					
						Promissory Note

					
					
						12

				
	
					
						(g)

					
					
						 

					
					
						Other Forms of Payment

					
					
						13

				
	
					
						(h)

					
					
						 

					
					
						Limitations under Applicable Law

					
					
						13

				
	
					
						SECTION 9.

					
					
						 

					
					
						STOCK APPRECIATION RIGHTS.

					
					
						13

				
	
					
						(a)

					
					
						 

					
					
						SAR Agreement

					
					
						13

				
	
					
						(b)

					
					
						 

					
					
						Number of Shares

					
					
						13

				
	
					
						(c)

					
					
						 

					
					
						Exercise Price

					
					
						13

				
	
					
						(d)

					
					
						 

					
					
						Exercisability and Term

					
					
						13

				
	
					
						(e)

					
					
						 

					
					
						Effect of Change in Control

					
					
						13

				
	
					
						(f)

					
					
						 

					
					
						Exercise of SARs

					
					
						13

				
	
					
						(g)

					
					
						 

					
					
						Modification or Assumption of SARs

					
					
						14

				
	
					
						(h)

					
					
						 

					
					
						Buyout Provisions

					
					
						14

				
	
					
						SECTION 10.

					
					
						 

					
					
						STOCK UNITS.

					
					
						14

				
	
					
						(a)

					
					
						 

					
					
						Stock Unit Agreement

					
					
						14

				
	
					
						(b)

					
					
						 

					
					
						Payment for Awards

					
					
						14

				
	
					
						(c)

					
					
						 

					
					
						Vesting Conditions

					
					
						14

				
	
					
						(d)

					
					
						 

					
					
						Voting and Dividend Rights

					
					
						14

				
	
					
						(e)

					
					
						 

					
					
						Form and Time of Settlement of Stock Units

					
					
						15

				
	
					
						(f)

					
					
						 

					
					
						Death of Recipient

					
					
						15

				
	
					
						(g)

					
					
						 

					
					
						Creditors’ Rights

					
					
						15

				
	
					
						SECTION 11.

					
					
						 

					
					
						ADJUSTMENT OF SHARES.

					
					
						15

				
	
					
						(a)

					
					
						 

					
					
						Adjustments

					
					
						15

				
	
					
						(b)

					
					
						 

					
					
						Dissolution or Liquidation

					
					
						16

				
	
					
						(c)

					
					
						 

					
					
						Reorganizations

					
					
						16

				
	
					
						(d)

					
					
						 

					
					
						Reservation of Rights

					
					
						16

				
	
					
						SECTION 12.

					
					
						 

					
					
						DEFERRAL OF AWARDS.

					
					
						17

				
	
					
						(a)

					
					
						 

					
					
						Committee Powers

					
					
						17

				
	
					
						(b)

					
					
						 

					
					
						General Rules

					
					
						17

				
	
					
						SECTION 13.

					
					
						 

					
					
						AWARDS UNDER OTHER PLANS.

					
					
						17

				

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  ii  -

		

 

		

			 

		

	
					
						

					
						SECTION 14.

					
					
						 

					
					
						PAYMENT OF DIRECTOR’S FEES IN SECURITIES.

					
					
						18

				
	
					
						(a)

					
					
						 

					
					
						Effective Date

					
					
						18

				
	
					
						(b)

					
					
						 

					
					
						Elections to Receive NSOs, Restricted Shares or Stock Units

					
					
						18

				
	
					
						(c)

					
					
						 

					
					
						Number and Terms of NSOs, Restricted Shares or Stock Units

					
					
						18

				
	
					
						SECTION 15.

					
					
						 

					
					
						LEGAL AND REGULATORY REQUIREMENTS.

					
					
						18

				
	
					
						SECTION 16.

					
					
						 

					
					
						TAXES.

					
					
						19

				
	
					
						(a)

					
					
						 

					
					
						Withholding Taxes

					
					
						19

				
	
					
						(b)

					
					
						 

					
					
						Share Withholding

					
					
						19

				
	
					
						(c)

					
					
						 

					
					
						Section 409A

					
					
						19

				
	
					
						SECTION 17.

					
					
						 

					
					
						OTHER PROVISIONS APPLICABLE TO AWARDS.

					
					
						20

				
	
					
						(a)

					
					
						 

					
					
						Transferability

					
					
						20

				
	
					
						(b)

					
					
						 

					
					
						Qualifying Performance Criteria

					
					
						20

				
	
					
						SECTION 18.

					
					
						 

					
					
						NO EMPLOYMENT RIGHTS.

					
					
						21

				
	
					
						SECTION 19.

					
					
						 

					
					
						DURATION AND AMENDMENTS.

					
					
						22

				
	
					
						(a)

					
					
						 

					
					
						Term of the Plan

					
					
						22

				
	
					
						(b)

					
					
						 

					
					
						Right to Amend or Terminate the Plan

					
					
						22

				
	
					
						(c)

					
					
						 

					
					
						Effect of Termination

					
					
						22

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  iii  -

		

 

		

			 

		

		

		
			GENOMIC HEALTH, INC.
		

		
			AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN
		

		
			(As amended on January 31, 2017)
		

			
	
			
				 SECTION 1.
			

			
	
			
			ESTABLISHMENT AND PURPOSE.

		
			The Plan was adopted by the Board of Directors on September 8, 2005, amended and restated on January 28, 2009, amended on July 25, 2013, amended and restated on March 19, 2014, amended on April 26, 2015, amended on January 26, 2016 and further amended on January 31, 2017.  The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a) encouraging Employees, Outside Directors and Consultants to focus on critical long-range objectives, (b) encouraging the attraction and retention of Employees, Outside Directors and Consultants with exceptional qualifications and (c) linking Employees, Outside Directors and Consultants directly to stockholder interests through increased stock ownership. The Plan seeks to achieve this purpose by providing for Awards in the form of restricted shares, stock units, options (which may constitute incentive stock options or nonstatutory stock options) or stock appreciation rights.
		

			
	
			
				 SECTION 2.
			

			
	
			
			DEFINITIONS.

			
	
			
				 (a)
			“Affiliate” shall mean any entity other than a Subsidiary, if the Company and/or one or more Subsidiaries own not less than 50% of such entity.

			
	
			
				 (b)
			“Award” shall mean any award of an Option, a SAR, a Restricted Share or a Stock Unit under the Plan.

			
	
			
				 (c)
			“Board of Directors” shall mean the Board of Directors of the Company, as constituted from time to time.

			
	
			
				 (d)
			“Change in Control” shall mean the occurrence of any of the following events:

			
	
			
				 (i)
			A change in the composition of the Board of Directors occurs, as a result of which fewer than one-half of the incumbent directors are directors who either:

			
	
			
				 (A)
			Had been directors of the Company on the “look-back date” (as defined below) (the “original directors”); or

			
	
			
				 (B)
			Were elected, or nominated for election, to the Board of Directors with the affirmative votes of at least a majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was previously so approved (the “continuing directors”); or

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  1  -

		

 

		

			 

		

		

			
	
			
				 (ii)
			Any “person” (as defined below) who by the acquisition or aggregation of securities, is or becomes the “beneficial owner” (as defined in Rule 13d‐3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding securities ordinarily (and apart from rights accruing under special circumstances) having the right to vote at elections of directors (the “Base Capital Stock”); except that any change in the relative beneficial ownership of the Company’s securities by any person resulting solely from a reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease thereafter in such person’s ownership of securities, shall be disregarded until such person increases in any manner, directly or indirectly, such person’s beneficial ownership of any securities of the Company; or

			
	
			
				 (iii)
			The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting power of the outstanding securities of each of (A) the continuing or surviving entity and (B) any direct or indirect parent corporation of such continuing or surviving entity; or

			
	
			
				 (iv)
			The sale, transfer or other disposition of all or substantially all of the Company’s assets.

		
			For purposes of subsection (d)(i) above, the term “look-back” date shall mean the date 24 months prior to the date of the event that may constitute a Change in Control.
		

		
			For purposes of subsection (d)(ii)) above, the term “person” shall have the same meaning as when used in Sections 13(d) and 14(d) of the Exchange Act but shall exclude (1) a trustee or other fiduciary holding securities under an employee benefit plan maintained by the Company or a Parent or Subsidiary and (2) a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the Stock.
		

		
			Any other provision of this Section 2(d) notwithstanding, a transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction, and a Change in Control shall not be deemed to occur if the Company files a registration statement with the United States Securities and Exchange Commission for the initial offering of Stock to the public.
		

			
	
			
				 (e)
			“Code” shall mean the Internal Revenue Code of 1986, as amended.

			
	
			
				 (f)
			“Committee” shall mean the Compensation Committee as designated by the Board of Directors, which is authorized to administer the Plan, as described in Section 3 hereof.

			
	
			
				 (g)
			“Company” shall mean Genomic Health, Inc., a Delaware corporation.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  2  -

		

 

		

			 

		

		

			
	
			
				 (h)
			“Consultant” shall mean a consultant or advisor who provides bona fide services to the Company, a Parent, a Subsidiary or an Affiliate as an independent contractor (not including service as a member of the Board of Directors) or a member of the board of directors of a Parent or a Subsidiary, in each case who is not an Employee.

			
	
			
				 (i)
			“Employee” shall mean any individual who is a common-law employee of the Company, a Parent, a Subsidiary or an Affiliate.

			
	
			
				 (j)
			“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

			
	
			
				 (k)
			“Exercise Price” shall mean, in the case of an Option, the amount for which one Share may be purchased upon exercise of such Option, as specified in the applicable Stock Option Agreement. “Exercise Price,” in the case of a SAR, shall mean an amount, as specified in the applicable SAR Agreement, which is subtracted from the Fair Market Value of one Share in determining the amount payable upon exercise of such SAR.

			
	
			
				 (l)
			“Fair Market Value” with respect to a Share, shall mean the market price of one Share, determined by the Committee as follows:

			
	
			
				 (i)
			If the Stock was traded over-the-counter on the date in question but was not traded on The Nasdaq Stock Market, then the Fair Market Value shall be equal to the last transaction price quoted for such date by the OTC Bulletin Board or, if not so quoted, shall be equal to the mean between the last reported representative bid and asked prices quoted for such date by the principal automated inter-dealer quotation system on which the Stock is quoted or, if the Stock is not quoted on any such system, by the Pink Sheets LLC;

			
	
			
				 (ii)
			If the Stock was traded on The Nasdaq Stock Market, then the Fair Market Value shall be equal to the last reported sale price quoted for such date by The Nasdaq Stock Market;

			
	
			
				 (iii)
			If the Stock was traded on a United States stock exchange on the date in question, then the Fair Market Value shall be equal to the closing price reported for such date by the applicable composite-transactions report; and

			
	
			
				 (iv)
			If none of the foregoing provisions is applicable, then the Fair Market Value shall be determined by the Committee in good faith on such basis as it deems appropriate.

		
			In all cases, the determination of Fair Market Value by the Committee shall be conclusive and binding on all persons.
		

			
	
			
				 (m)
			“ISO” shall mean an employee incentive stock option described in Section 422 of the Code.

			
	
			
				 (n)
			“Nonstatutory Option” or “NSO” shall mean an employee stock option that is not an ISO.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  3  -

		

 

		

			 

		

		

			
	
			
				 (o)
			“Offeree” shall mean an individual to whom the Committee has offered the right to acquire Shares under the Plan (other than upon exercise of an Option).

			
	
			
				 (p)
			“Option” shall mean an ISO or Nonstatutory Option granted under the Plan and entitling the holder to purchase Shares.

			
	
			
				 (q)
			“Optionee” shall mean an individual or estate who holds an Option or SAR.

			
	
			
				 (r)
			“Outside Director” shall mean a member of the Board of Directors who is not a common-law employee of, or paid consultant to, the Company, a Parent or a Subsidiary.

			
	
			
				 (s)
			“Parent” shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the adoption of the Plan shall be a Parent commencing as of such date.

			
	
			
				 (t)
			“Participant” shall mean an individual or estate who holds an Award.

			
	
			
				 (u)
			“Plan” shall mean this 2005 Stock Incentive Plan of Genomic Health, Inc., as amended from time to time.

			
	
			
				 (v)
			“Purchase Price” shall mean the consideration for which one Share may be acquired under the Plan (other than upon exercise of an Option), as specified by the Committee.

			
	
			
				 (w)
			“Restricted Share” shall mean a Share awarded under the Plan.

			
	
			
				 (x)
			“Restricted Share Agreement” shall mean the agreement between the Company and the recipient of a Restricted Share which contains the terms, conditions and restrictions pertaining to such Restricted Shares.

			
	
			
				 (y)
			“SAR” shall mean a stock appreciation right granted under the Plan.

			
	
			
				 (z)
			“SAR Agreement” shall mean the agreement between the Company and an Optionee which contains the terms, conditions and restrictions pertaining to his or her SAR.

			
	
			
				 (aa)
			“Service” shall mean service as an Employee, Consultant or Outside Director, subject to such further limitations as may be set forth in the Plan or the applicable Stock Option Agreement, SAR Agreement, Restricted Share Agreement or Stock Unit Agreement. Service does not terminate when an Employee goes on a bona fide leave of absence, that was approved by the Company in writing, if the terms of the leave provide for continued Service crediting, or when continued Service crediting is required by applicable law. However, for purposes of determining whether an Option is entitled to ISO status, an Employee’s employment will be treated as terminating three months after such Employee went on leave, unless such Employee’s right to return to active work is guaranteed by law or by a contract. Service terminates in any event when the approved leave ends, unless such Employee immediately returns to active work. The Company determines which leaves count toward Service, and when Service terminates for all purposes under the Plan.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  4  -

		

 

		

			 

		

		

			
	
			
				 (bb)
			“Share” shall mean one share of Stock, as adjusted in accordance with Section 11 (if applicable). All share numbers herein assume, and no adjustment shall be made in respect of, the one-for-three reverse split of the Stock approved by the Board of Directors on the date of initial adoption of the Plan.

			
	
			
				 (cc)
			“Stock” shall mean the Common Stock of the Company.

			
	
			
				 (dd)
			“Stock Option Agreement” shall mean the agreement between the Company and an Optionee that contains the terms, conditions and restrictions pertaining to such Option.

			
	
			
				 (ee)
			“Stock Unit” shall mean a bookkeeping entry representing the equivalent of one Share, as awarded under the Plan.

			
	
			
				 (ff)
			“Stock Unit Agreement” shall mean the agreement between the Company and the recipient of a Stock Unit which contains the terms, conditions and restrictions pertaining to such Stock Unit.

			
	
			
				 (gg)
			“Subsidiary” shall mean any corporation, if the Company and/or one or more other Subsidiaries own not less than 50% of the total combined voting power of all classes of outstanding stock of such corporation. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date.

		
			(hh)“Total and Permanent Disability” shall mean permanent and total disability as defined by section 22(e)(3) of the Code.
		

			
	
			
				 SECTION 3.
			

			
	
			
			ADMINISTRATION.

			
	
			
				 (a)
			Committee Composition. The Plan shall be administered by the Committee. The Committee shall consist of two or more directors of the Company, who shall be appointed by the Board. In addition, the composition of the Committee shall satisfy (i) such requirements as the Securities and Exchange Commission may establish for administrators acting under plans intended to qualify for exemption under Rule 16b-3 (or its successor) under the Exchange Act; and (ii) such requirements as the Internal Revenue Service may establish for outside directors acting under plans intended to qualify for exemption under Section 162(m)(4)(C) of the Code.

			
	
			
				 (b)
			Committee for Non-Officer Grants. The Board may also appoint one or more separate committees of the Board, each composed of one or more directors of the Company who need not satisfy the requirements of Section 3(a), who may administer the Plan with respect to Employees who are not considered officers or directors of the Company under Section 16 of the Exchange Act, may grant Awards under the Plan to such Employees and may determine all terms of such grants. Within the limitations of the preceding sentence, any reference in the Plan to the Committee shall include such committee or committees appointed pursuant to the preceding sentence. The Board of Directors may also authorize one or more officers of the Company to designate Employees, other than officers under Section 16 of the Exchange Act, to receive Awards and/or to determine the number of such Awards to be received by such persons; provided, however, that the Board of Directors shall specify the total number of Awards that such officers may so award.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  5  -

		

 

		

			 

		

		

			
	
			
				 (c)
			Committee Procedures. The Board of Directors shall designate one of the members of the Committee as chairman. The Committee may hold meetings at such times and places as it shall determine. The acts of a majority of the Committee members present at meetings at which a quorum exists, or acts reduced to or approved in writing (including via email) by all Committee members, shall be valid acts of the Committee.

			
	
			
				 (d)
			Committee Responsibilities. Subject to the provisions of the Plan, the Committee shall have full authority and discretion to take the following actions:

			
	
			
				 (i)
			To interpret the Plan and to apply its provisions;

			
	
			
				 (ii)
			To adopt, amend or rescind rules, procedures and forms relating to the Plan;

			
	
			
				 (iii)
			To adopt, amend or terminate sub-plans established for the purpose of satisfying applicable foreign laws including qualifying for preferred tax treatment under applicable foreign tax laws;

			
	
			
				 (iv)
			To authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan;

			
	
			
				 (v)
			To determine when Awards are to be granted under the Plan;

			
	
			
				 (vi)
			To select the Offerees and Optionees;

			
	
			
				 (vii)
			To determine the number of Shares to be made subject to each Award;

			
	
			
				 (viii)
			To prescribe the terms and conditions of each Award, including (without limitation) the Exercise Price and Purchase Price, and the vesting or duration of the Award (including accelerating the vesting of Awards, either at the time of the Award or thereafter, without the consent of the Participant), to determine whether an Option is to be classified as an ISO or as a Nonstatutory Option, and to specify the provisions of the agreement relating to such Award;

			
	
			
				 (ix)
			To amend any outstanding Award agreement, subject to applicable legal restrictions and to the consent of the Participant if the Participant’s rights or obligations would be materially impaired;

			
	
			
				 (x)
			To prescribe the consideration for the grant of each Award or other right under the Plan and to determine the sufficiency of such consideration;

			
	
			
				 (xi)
			To determine the disposition of each Award or other right under the Plan in the event of a Participant’s divorce or dissolution of marriage;

			
	
			
				 (xii)
			To determine whether Awards under the Plan will be granted in replacement of other grants under an incentive or other compensation plan of an acquired business;

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  6  -

		

 

		

			 

		

		

			
	
			
				 (xiii)
			To correct any defect, supply any omission, or reconcile any inconsistency in the Plan or any Award agreement;

			
	
			
				 (xiv)
			To establish or verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, exercisability, vesting and/or ability to retain any Award; and

			
	
			
				 (xv)
			To take any other actions deemed necessary or advisable for the administration of the Plan.

		
			Subject to the requirements of applicable law, the Committee may designate persons other than members of the Committee to carry out its responsibilities and may prescribe such conditions and limitations as it may deem appropriate, except that the Committee may not delegate its authority with regard to the selection for participation of or the granting of Options or other rights under the Plan to persons subject to Section 16 of the Exchange Act. All decisions, interpretations and other actions of the Committee shall be final and binding on all Offerees, all Optionees, and all persons deriving their rights from an Offeree or Optionee. No member of the Committee shall be liable for any action that he has taken or has failed to take in good faith with respect to the Plan, any Option, or any right to acquire Shares under the Plan.
		

			
	
			
				 SECTION 4.
			

			
	
			
			ELIGIBILITY.

			
	
			
				 (a)
			General Rule. Only common-law employees of the Company, a Parent or a Subsidiary shall be eligible for the grant of ISOs. Only Employees, Consultants and Outside Directors shall be eligible for the grant of Restricted Shares, Stock Units, Nonstatutory Options or SARs.

			
	
			
				 (b)
			Automatic Grants to Outside Directors.

			
	
			
				 (i)
			Each Outside Director who first joins the Board of Directors on or after the effective date of the Plan, and who was not previously an Employee, shall receive a Nonstatutory Option, subject to approval of the Plan by the Company’s stockholders, to purchase 20,000 Shares (subject to adjustment under Section 11) on the date of his or her election to the Board of Directors. Twenty-five percent (25%) of the Shares subject to each Option granted under this Section 4(b)(i) shall vest and become exercisable on the first anniversary of the date of grant. The balance of the Shares subject to such Option (i.e. the remaining seventy-five percent  (75%)) shall vest and become exercisable monthly over a three-year period beginning on the day which is one month after the first anniversary of the date of grant, at a monthly rate of 2.0833% of the total number of Shares subject to such Option. Notwithstanding the foregoing, each such Option shall become vested if a Change in Control occurs with respect to the Company during the Optionee’s Service.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  7  -

		

 

		

			 

		

		

			
	
			
				 (ii)
			On the first business day following the conclusion of each regular annual meeting of the Company’s stockholders, each Outside Director who was not elected to the Board for the first time at such meeting and who will continue serving as a member of the Board of Directors thereafter shall receive an Option to purchase 10,000 Shares (subject to adjustment under Section 11), provided that such Outside Director has served on the Board of Directors for at least six months. Each Option granted under this Section 4(b)(ii) shall vest and become exercisable on the first anniversary of the date of grant; provided, however, that each such Option shall become exercisable in full immediately prior to the next regular annual meeting of the Company’s stockholders following such date of grant in the event such meeting occurs prior to such first anniversary date. Notwithstanding the foregoing, each Option granted under this Section 4(b)(ii) shall become vested if a Change in Control occurs with respect to the Company during the Optionee’s Service.

			
	
			
				 (iii)
			The Exercise Price of all Nonstatutory Options granted to an Outside Director under this Section 4(b) shall be equal to 100% of the Fair Market Value of a Share on the date of grant, payable in one of the forms described in Section 8(a), (b) or (d).

			
	
			
				 (iv)
			All Nonstatutory Options granted to an Outside Director under this Section 4(b) shall terminate on the earlier of (A) the day before the tenth anniversary of the date of grant of such Options or (B) the date twelve months after the termination of such Outside Director’s Service for any reason; provided, however, that any such Options that are not vested upon the termination of the Outside Director’s Service as a member of the Board of Directors for any reason shall terminate immediately and may not be exercised.

			
	
			
				 (c)
			Ten-Percent Stockholders. An Employee who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company, a Parent or Subsidiary shall not be eligible for the grant of an ISO unless such grant satisfies the requirements of Section 422(c)(5) of the Code.

			
	
			
				 (d)
			Attribution Rules. For purposes of Section 4(c) above, in determining stock ownership, an Employee shall be deemed to own the stock owned, directly or indirectly, by or for such Employee’s brothers, sisters, spouse, ancestors and lineal descendants. Stock owned, directly or indirectly, by or for a corporation, partnership, estate or trust shall be deemed to be owned proportionately by or for its stockholders, partners or beneficiaries.

			
	
			
				 (e)
			Outstanding Stock. For purposes of Section 4(c) above, “outstanding stock” shall include all stock actually issued and outstanding immediately after the grant. “Outstanding stock” shall not include shares authorized for issuance under outstanding options held by the Employee or by any other person.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  8  -

		

 

		

			 

		

		

			
	
			
				 SECTION 5.
			

			
	
			
			STOCK SUBJECT TO PLAN.

			
	
			
				 (a)
			Basic Limitation. Shares offered under the Plan shall be authorized but unissued Shares or treasury Shares. The aggregate number of Shares authorized for issuance as Awards under the Plan shall not exceed 13,480,000 Shares (the “Absolute Share Limit”). The limitations of this Section 5(a) shall be subject to adjustment pursuant to Section 11. The number of Shares that are subject to Options or other Awards outstanding at any time under the Plan shall not exceed the number of Shares which then remain available for issuance under the Plan. The Company, during the term of the Plan, shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan.

			
	
			
				 (b)
			Award Limitation. Subject to the provisions of Section 11, no Participant may receive Options, SARs, Restricted Shares or Stock Units under the Plan in any calendar year that relate to more than 1,650,000 Shares.

			
	
			
				 (c)
			Additional Shares. If Restricted Shares or Shares issued upon the exercise of Options are forfeited, then such Shares shall again become available for Awards under the Plan. If Stock Units, Options or SARs are forfeited or terminate for any other reason before being exercised, then the corresponding Shares shall again become available for Awards under the Plan. If Stock Units are settled, then only the number of Shares (if any) actually issued in settlement of such Stock Units shall reduce the number available under Section 5(a) and the balance shall again become available for Awards under the Plan. If SARs are exercised, then only the number of Shares (if any) actually issued in settlement of such SARs shall reduce the number available in Section 5(a) and the balance shall again become available for Awards under the Plan. Notwithstanding the foregoing, the number of Shares that may be delivered in the aggregate pursuant to the exercise of ISOs granted under the Plan shall not exceed the Absolute Share Limit, as adjusted pursuant to Section 11, plus, to the extent allowable under Section 422 of the Code and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to this Section 5(c).

			
	
			
				 SECTION 6.
			

			
	
			
			RESTRICTED SHARES.

			
	
			
				 (a)
			Restricted Stock Agreement. Each grant of Restricted Shares under the Plan shall be evidenced by a Restricted Stock Agreement between the recipient and the Company. Such Restricted Shares shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various Restricted Stock Agreements entered into under the Plan need not be identical.

			
	
			
				 (b)
			Payment for Awards.  Restricted Shares may be sold or awarded under the Plan for such consideration as the Committee may determine, including (without limitation) cash, cash equivalents, full-recourse promissory notes, past services and future services.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  9  -

		

 

		

			 

		

		

			
	
			
				 (c)
			Vesting. Each Award of Restricted Shares may or may not be subject to vesting. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Restricted Stock Agreement. A Restricted Stock Agreement may provide for accelerated vesting in the event of the Participant’s death, disability or retirement or other events. The Committee may determine, at the time of granting Restricted Shares of thereafter, that all or part of such Restricted Shares shall become vested in the event that a Change in Control occurs with respect to the Company.

			
	
			
				 (d)
			Voting and Dividend Rights. The holders of Restricted Shares awarded under the Plan shall have the same voting, dividend and other rights as the Company’s other stockholders. A Restricted Stock Agreement, however, may require that the holders of Restricted Shares invest any cash dividends received in additional Restricted Shares. Such additional Restricted Shares shall be subject to the same conditions and restrictions as the Award with respect to which the dividends were paid.

			
	
			
				 (e)
			Restrictions on Transfer of Shares. Restricted Shares shall be subject to such rights of repurchase, rights of first refusal or other restrictions as the Committee may determine. Such restrictions shall be set forth in the applicable Restricted Stock Agreement and shall apply in addition to any general restrictions that may apply to all holders of Shares.

			
	
			
				 SECTION 7.
			

			
	
			
			TERMS AND CONDITIONS OF OPTIONS.

			
	
			
				 (a)
			Stock Option Agreement. Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement between the Optionee and the Company. Such Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan and which the Committee deems appropriate for inclusion in a Stock Option Agreement. The Stock Option Agreement shall specify whether the Option is an ISO or an NSO. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. Options may be granted in consideration of a reduction in the Optionee’s other compensation.

			
	
			
				 (b)
			Number of Shares. Each Stock Option Agreement shall specify the number of Shares that are subject to the Option and shall provide for the adjustment of such number in accordance with Section 11.

			
	
			
				 (c)
			Exercise Price. Each Stock Option Agreement shall specify the Exercise Price. The Exercise Price of an ISO shall not be less than 100% of the Fair Market Value of a Share on the date of grant, except as otherwise provided in 4(c), and the Exercise Price of an NSO shall not be less 85% of the Fair Market Value of a Share on the date of grant. Subject to the foregoing in this Section 7(c), the Exercise Price under any Option shall be determined by the Committee at its sole discretion. The Exercise Price shall be payable in one of the forms described in Section 8.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  10  -

		

 

		

			 

		

		

			
	
			
				 (d)
			Withholding Taxes. As a condition to the exercise of an Option, the Optionee shall make such arrangements as the Committee may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with such exercise. The Optionee shall also make such arrangements as the Committee may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with the disposition of Shares acquired by exercising an Option.

			
	
			
				 (e)
			Exercisability and Term. Each Stock Option Agreement shall specify the date when all or any installment of the Option is to become exercisable. The Stock Option Agreement shall also specify the term of the Option; provided that the term of an ISO shall in no event exceed 10 years from the date of grant (five years for Employees described in Section 4(c)). A Stock Option Agreement may provide for accelerated exercisability in the event of the Optionee’s death, disability, or retirement or other events and may provide for expiration prior to the end of its term in the event of the termination of the Optionee’s Service. Options may be awarded in combination with SARs, and such an Award may provide that the Options will not be exercisable unless the related SARs are forfeited. Subject to the foregoing in this Section 7(e), the Committee at its sole discretion shall determine when all or any installment of an Option is to become exercisable and when an Option is to expire.

			
	
			
				 (f)
			Exercise of Options.  Each Stock Option Agreement shall set forth the extent to which the Optionee shall have the right to exercise the Option following termination of the Optionee’s Service with the Company and its Subsidiaries, and the right to exercise the Option of any executors or administrators of the Optionee’s estate or any person who has acquired such Option(s) directly from the Optionee by bequest or inheritance. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Options issued pursuant to the Plan, and may reflect distinctions based on the reasons for termination of Service.

			
	
			
				 (g)
			Effect of Change in Control. The Committee may determine, at the time of granting an Option or thereafter, that such Option shall become exercisable as to all or part of the Shares subject to such Option in the event that a Change in Control occurs with respect to the Company.

			
	
			
				 (h)
			No Rights as a Stockholder. An Optionee, or a transferee of an Optionee, shall have no rights as a stockholder with respect to any Shares covered by his Option until the date of the issuance of a stock certificate for such Shares. No adjustments shall be made, except as provided in Section 11.

			
	
			
				 (i)
			Modification, Extension and Renewal of Options. Within the limitations of the Plan, the Committee may modify, extend or renew outstanding options or may accept the cancellation of outstanding options (to the extent not previously exercised), whether or not granted hereunder, in return for the grant of new Options for the same or a different number of Shares and at the same or a different exercise price, or in return for the grant of the same or a different number of Shares. The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, materially impair his or her rights or obligations under such Option.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  11  -

		

 

		

			 

		

		

			
	
			
				 (j)
			Restrictions on Transfer of Shares. Any Shares issued upon exercise of an Option shall be subject to such special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Committee may determine. Such restrictions shall be set forth in the applicable Stock Option Agreement and shall apply in addition to any general restrictions that may apply to all holders of Shares.

			
	
			
				 (k)
			Buyout Provisions. The Committee may at any time (a) offer to buy out for a payment in cash or cash equivalents an Option previously granted or (b) authorize an Optionee to elect to cash out an Option previously granted, in either case at such time and based upon such terms and conditions as the Committee shall establish.

			
	
			
				 SECTION 8.
			

			
	
			
			PAYMENT FOR SHARES.

			
	
			
				 (a)
			General Rule. The entire Exercise Price or Purchase Price of Shares issued under the Plan shall be payable in lawful money of the United States of America at the time when such Shares are purchased, except as provided in Section 8(b) through Section 8(g) below.

			
	
			
				 (b)
			Surrender of Stock. To the extent that a Stock Option Agreement so provides, payment may be made all or in part by surrendering, or attesting to the ownership of, Shares which have already been owned by the Optionee or his representative. Such Shares shall be valued at their Fair Market Value on the date when the new Shares are purchased under the Plan. The Optionee shall not surrender, or attest to the ownership of, Shares in payment of the Exercise Price if such action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to the Option for financial reporting purposes.

			
	
			
				 (c)
			Services Rendered. At the discretion of the Committee, Shares may be awarded under the Plan in consideration of services rendered to the Company or a Subsidiary prior to the award. If Shares are awarded without the payment of a Purchase Price in cash, the Committee shall make a determination (at the time of the award) of the value of the services rendered by the Offeree and the sufficiency of the consideration to meet the requirements of Section 6(b).

			
	
			
				 (d)
			Cashless Exercise. To the extent that a Stock Option Agreement so provides, payment may be made all or in part by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the aggregate Exercise Price.

			
	
			
				 (e)
			Exercise/Pledge. To the extent that a Stock Option Agreement so provides, payment may be made all or in part by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker or lender to pledge Shares, as security for a loan, and to deliver all or part of the loan proceeds to the Company in payment of the aggregate Exercise Price.

			
	
			
				 (f)
			Promissory Note. To the extent that a Stock Option Agreement or Restricted Stock Agreement so provides, payment may be made all or in part by delivering (on a form prescribed by the Company) a full-recourse promissory note.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  12  -

		

 

		

			 

		

		

			
	
			
				 (g)
			Other Forms of Payment. To the extent that a Stock Option Agreement or Restricted Stock Agreement so provides, payment may be made in any other form that is consistent with applicable laws, regulations and rules.

			
	
			
				 (h)
			Limitations under Applicable Law. Notwithstanding anything herein or in a Stock Option Agreement or Restricted Stock Agreement to the contrary, payment may not be made in any form that is unlawful, as determined by the Committee in its sole discretion.

			
	
			
				 SECTION 9.
			

			
	
			
			STOCK APPRECIATION RIGHTS.

			
	
			
				 (a)
			SAR Agreement. Each grant of a SAR under the Plan shall be evidenced by a SAR Agreement between the Optionee and the Company. Such SAR shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various SAR Agreements entered into under the Plan need not be identical. SARs may be granted in consideration of a reduction in the Optionee’s other compensation.

			
	
			
				 (b)
			Number of Shares. Each SAR Agreement shall specify the number of Shares to which the SAR pertains and shall provide for the adjustment of such number in accordance with Section 11.

			
	
			
				 (c)
			Exercise Price. Each SAR Agreement shall specify the Exercise Price. A SAR Agreement may specify an Exercise Price that varies in accordance with a predetermined formula while the SAR is outstanding.

			
	
			
				 (d)
			Exercisability and Term. Each SAR Agreement shall specify the date when all or any installment of the SAR is to become exercisable. The SAR Agreement shall also specify the term of the SAR. A SAR Agreement may provide for accelerated exercisability in the event of the Optionee’s death, disability or retirement or other events and may provide for expiration prior to the end of its term in the event of the termination of the Optionee’s service. SARs may be awarded in combination with Options, and such an Award may provide that the SARs will not be exercisable unless the related Options are forfeited. A SAR may be included in an ISO only at the time of grant but may be included in an NSO at the time of grant or thereafter. A SAR granted under the Plan may provide that it will be exercisable only in the event of a Change in Control.

			
	
			
				 (e)
			Effect of Change in Control. The Committee may determine, at the time of granting a SAR or thereafter, that such SAR shall become fully exercisable as to all Common Shares subject to such SAR in the event that a Change in Control occurs with respect to the Company.

			
	
			
				 (f)
			Exercise of SARs. Upon exercise of a SAR, the Optionee (or any person having the right to exercise the SAR after his or her death) shall receive from the Company (a) Shares, (b) cash or (c) a combination of Shares and cash, as the Committee shall determine. The amount of cash and/or the Fair Market Value of Shares received upon exercise of SARs shall, in the aggregate, be equal to the amount by which the Fair Market Value (on the date of surrender) of the Shares subject to the SARs exceeds the Exercise Price.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  13  -

		

 

		

			 

		

		

			
	
			
				 (g)
			Modification or Assumption of SARs. Within the limitations of the Plan, the Committee may modify, extend or assume outstanding SARs or may accept the cancellation of outstanding SARs (whether granted by the Company or by another issuer) in return for the grant of new SARs for the same or a different number of shares and at the same or a different exercise price. The foregoing notwithstanding, no modification of a SAR shall, without the consent of the holder, materially impair his or her rights or obligations under such SAR.

			
	
			
				 (h)
			Buyout Provisions. The Committee may at any time (a) offer to buy out for a payment in cash or cash equivalents a SAR previously granted, or (b) authorize an Optionee to elect to cash out a SAR previously granted, in either case at such time and based upon such terms and conditions as the Committee shall establish.

			
	
			
				 SECTION 10.
			

			
	
			
			STOCK UNITS.

			
	
			
				 (a)
			Stock Unit Agreement. Each grant of Stock Units under the Plan shall be evidenced by a Stock Unit Agreement between the recipient and the Company. Such Stock Units shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various Stock Unit Agreements entered into under the Plan need not be identical. Stock Units may be granted in consideration of a reduction in the recipient’s other compensation.

			
	
			
				 (b)
			Payment for Awards. To the extent that an Award is granted in the form of Stock Units, no cash consideration shall be required of the Award recipients.

			
	
			
				 (c)
			Vesting Conditions. Each Award of Stock Units may or may not be subject to vesting. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Stock Unit Agreement. A Stock Unit Agreement may provide for accelerated vesting in the event of the Participant’s death, disability or retirement or other events. The Committee may determine, at the time of granting Stock Units or thereafter, that all or part of such Stock Units shall become vested in the event that a Change in Control occurs with respect to the Company.

			
	
			
				 (d)
			Voting and Dividend Rights. The holders of Stock Units shall have no voting rights. Prior to settlement or forfeiture, any Stock Unit awarded under the Plan may, at the Committee’s discretion, carry with it a right to dividend equivalents. Such right entitles the holder to be credited with an amount equal to all cash dividends paid on one Share while the Stock Unit is outstanding. Dividend equivalents may be converted into additional Stock Units. Settlement of dividend equivalents may be made in the form of cash, in the form of Shares, or in a combination of both. Prior to distribution, any dividend equivalents which are not paid shall be subject to the same conditions and restrictions (including without limitation, any forfeiture conditions) as the Stock Units to which they attach.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  14  -

		

 

		

			 

		

		

			
	
			
				 (e)
			Form and Time of Settlement of Stock Units. Settlement of vested Stock Units may be made in the form of (a) cash, (b) Shares or (c) any combination of both, as determined by the Committee. The actual number of Stock Units eligible for settlement may be larger or smaller than the number included in the original Award, based on predetermined performance factors. Methods of converting Stock Units into cash may include (without limitation) a method based on the average Fair Market Value of Shares over a series of trading days. Vested Stock Units may be settled in a lump sum or in installments. The distribution may occur or commence when all vesting conditions applicable to the Stock Units have been satisfied or have lapsed, or it may be deferred to any later date. The amount of a deferred distribution may be increased by an interest factor or by dividend equivalents. Until an Award of Stock Units is settled, the number of such Stock Units shall be subject to adjustment pursuant to Section 11.

			
	
			
				 (f)
			Death of Recipient. Any Stock Units Award that becomes payable after the recipient’s death shall be distributed to the recipient’s beneficiary or beneficiaries. Each recipient of a Stock Units Award under the Plan shall designate one or more beneficiaries for this purpose by filing the prescribed form with the Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Award recipient’s death. If no beneficiary was designated or if no designated beneficiary survives the Award recipient, then any Stock Units Award that becomes payable after the recipient’s death shall be distributed to the recipient’s estate.

			
	
			
				 (g)
			Creditors’ Rights. A holder of Stock Units shall have no rights other than those of a general creditor of the Company. Stock Units represent an unfunded and unsecured obligation of the Company, subject to the terms and conditions of the applicable Stock Unit Agreement.

			
	
			
				 SECTION 11.
			

			
	
			
			ADJUSTMENT OF SHARES.

			
	
			
				 (a)
			Adjustments. In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in Shares, a declaration of a dividend payable in a form other than Shares in an amount that has a material effect on the price of Shares, a combination or consolidation of the outstanding Stock (by reclassification or otherwise) into a lesser number of Shares, a recapitalization, a spin-off or a similar occurrence, the Committee shall make appropriate and equitable adjustments in:

			
	
			
				 (i)
			The number of Options, SARs, Restricted Shares and Stock Units available for future Awards under Section 5;

			
	
			
				 (ii)
			The limitations set forth in Section 5(b);

			
	
			
				 (iii)
			The number of NSOs to be granted to Outside Directors under Section 4(b);

			
	
			
				 (iv)
			The number of Shares covered by each outstanding Option and SAR;

			
	
			
				 (v)
			The Exercise Price under each outstanding Option and SAR; and

			
	
			
				 (vi)
			The number of Stock Units included in any prior Award which has not yet been settled.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  15  -

		

 

		

			 

		

		

		
			Except as provided in this Section 11, a Participant shall have no rights by reason of any issue by the Company of stock of any class or securities convertible into stock of any class, any subdivision or consolidation of shares of stock of any class, the payment of any stock dividend or any other increase or decrease in the number of shares of stock of any class.
		

			
	
			
				 (b)
			Dissolution or Liquidation. To the extent not previously exercised or settled, Options, SARs and Stock Units shall terminate immediately prior to the dissolution or liquidation of the Company.

			
	
			
				 (c)
			Reorganizations. In the event that the Company is a party to a merger or other reorganization, outstanding Awards shall be subject to the agreement of merger or reorganization. Subject to compliance with Section 409A of the Code, such agreement shall provide for:

			
	
			
				 (i)
			The continuation of the outstanding Awards by the Company, if the Company is a surviving corporation;

			
	
			
				 (ii)
			The assumption of the outstanding Awards by the surviving corporation or its parent or subsidiary;

			
	
			
				 (iii)
			The substitution by the surviving corporation or its parent or subsidiary of its own awards for the outstanding Awards;

			
	
			
				 (iv)
			Full exercisability or vesting and accelerated expiration of the outstanding Awards; or

			
	
			
				 (v)
			Settlement of the full value of the outstanding Awards in cash or cash equivalents followed by cancellation of such Awards.

			
	
			
				 (d)
			Reservation of Rights. Except as provided in this Section 11, an Optionee or Offeree shall have no rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of Shares subject to an Option. The grant of an Option pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  16  -

		

 

		

			 

		

		

			
	
			
				 SECTION 12.
			

			
	
			
			DEFERRAL OF AWARDS.

			
	
			
				 (a)
			Committee Powers.  Subject to compliance with Section 409A of the Code, the Committee (in its sole discretion) may permit or require a Participant to:

			
	
			
				 (i)
			Have cash that otherwise would be paid to such Participant as a result of the exercise of a SAR or the settlement of Stock Units credited to a deferred compensation account established for such Participant by the Committee as an entry on the Company’s books;

			
	
			
				 (ii)
			Have Shares that otherwise would be delivered to such Participant as a result of the exercise of an Option or SAR converted into an equal number of Stock Units; or

			
	
			
				 (iii)
			Have Shares that otherwise would be delivered to such Participant as a result of the exercise of an Option or SAR or the settlement of Stock Units converted into amounts credited to a deferred compensation account established for such Participant by the Committee as an entry on the Company’s books. Such amounts shall be determined by reference to the Fair Market Value of such Shares as of the date when they otherwise would have been delivered to such Participant.

			
	
			
				 (b)
			General Rules. A deferred compensation account established under this Section 12 may be credited with interest or other forms of investment return, as determined by the Committee. A Participant for whom such an account is established shall have no rights other than those of a general creditor of the Company. Such an account shall represent an unfunded and unsecured obligation of the Company and shall be subject to the terms and conditions of the applicable agreement between such Participant and the Company. If the deferral or conversion of Awards is permitted or required, the Committee (in its sole discretion) may establish rules, procedures and forms pertaining to such Awards, including (without limitation) the settlement of deferred compensation accounts established under this Section 12.

			
	
			
				 SECTION 13.
			

			
	
			
			AWARDS UNDER OTHER PLANS.

		
			The Company may grant awards under other plans or programs. Such awards may be settled in the form of Shares issued under this Plan. Such Shares shall be treated for all purposes under the Plan like Shares issued in settlement of Stock Units and shall, when issued, reduce the number of Shares available under Section 5.
		

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  17  -

		

 

		

			 

		

		

			
	
			
				 SECTION 14.
			

			
	
			
			PAYMENT OF DIRECTOR’S FEES IN SECURITIES.

			
	
			
				 (a)
			Effective Date. No provision of this Section 14 shall be effective unless and until the Board has determined to implement such provision.

			
	
			
				 (b)
			Elections to Receive NSOs, Restricted Shares or Stock Units. An Outside Director may elect to receive his or her annual retainer payments and/or meeting fees from the Company in the form of cash, NSOs, Restricted Shares or Stock Units, or a combination thereof, as determined by the Board. Such NSOs, Restricted Shares and Stock Units shall be issued under the Plan. An election under this Section 14 shall be filed with the Company on the prescribed form.

			
	
			
				 (c)
			Number and Terms of NSOs, Restricted Shares or Stock Units. The number of NSOs, Restricted Shares or Stock Units to be granted to Outside Directors in lieu of annual retainers and meeting fees that would otherwise be paid in cash shall be calculated in a manner determined by the Board. The terms of such NSOs, Restricted Shares or Stock Units shall also be determined by the Board.

			
	
			
				 SECTION 15.
			

			
	
			
			LEGAL AND REGULATORY REQUIREMENTS.

		
			Shares shall not be issued under the Plan unless the issuance and delivery of such Shares complies with (or is exempt from) all applicable requirements of law, including (without limitation) the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder, state securities laws and regulations and the regulations of any stock exchange on which the Company’s securities may then be listed, and the Company has obtained the approval or favorable ruling from any governmental agency which the Company determines is necessary or advisable. The Company shall not be liable to a Participant or other persons as to: (a) the non-issuance or sale of Shares as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares under the Plan; and (b) any tax consequences expected, but not realized, by any Participant or other person due to the receipt, exercise or settlement of any Award granted under the Plan.
		

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  18  -

		

 

		

			 

		

		

			
	
			
				 SECTION 16.
			

			
	
			
			TAXES.

			
	
			
				 (a)
			Withholding Taxes. To the extent required by applicable federal, state, local or foreign law, a Participant or his or her successor shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company shall not be required to issue any Shares or make any cash payment under the Plan until such obligations are satisfied.

			
	
			
				 (b)
			Share Withholding. The Committee may permit a Participant to satisfy all or part of his or her withholding or income tax obligations by having the Company withhold all or a portion of any Shares that otherwise would be issued to him or her or by surrendering all or a portion of any Shares that he or she previously acquired. Such Shares shall be valued at their Fair Market Value on the date when taxes otherwise would be withheld in cash. In no event may a Participant have Shares withheld that would otherwise be issued to him or her in excess of the number necessary to satisfy the legally required minimum tax withholding. Each Award that provides for “nonqualified deferred compensation” within the meaning of Section 409A of the Code shall be subject to such additional rules and requirements as specified by the Committee from time to time in order to comply with Section 409A. If any amount under such an Award is payable upon a “separation from service” (within the meaning of Section 409A) to a Participant who is then considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the Participant’s separation from service, or (ii) the Participant’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. In addition, the settlement of any such Award may not be accelerated except to the extent permitted by Section 409A.

			
	
			
				 (c)
			Section 409A. Each Award that provides for “nonqualified deferred compensation” within the meaning of Section 409A of the Code shall be subject to such additional rules and requirements as specified by the Committee from time to time in order to comply with Section 409A. If any amount under such an Award is payable upon a “separation from service” (within the meaning of Section 409A) to a Participant who is then considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the Participant’s separation from service, or (ii) the Participant’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. In addition, the settlement of any such Award may not be accelerated except to the extent permitted by Section 409A.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  19  -

		

 

		

			 

		

		

			
	
			
				 SECTION 17.
			

			
	
			
			OTHER PROVISIONS APPLICABLE TO AWARDS.

			
	
			
				 (a)
			Transferability. Unless the agreement evidencing an Award (or an amendment thereto authorized by the Committee) expressly provides otherwise, no Award granted under this Plan, nor any interest in such Award, may be sold, assigned, conveyed, gifted, pledged, hypothecated or otherwise transferred in any manner (prior to the vesting and lapse of any and all restrictions applicable to Shares issued under such Award), other than by will or the laws of descent and distribution; provided, however, that an ISO may be transferred or assigned only to the extent consistent with Section 422 of the Code. Any purported assignment, transfer or encumbrance in violation of this Section 17(a) shall be void and unenforceable against the Company.

			
	
			
				 (b)
			Qualifying Performance Criteria.  The number of Shares or other benefits granted, issued, retainable and/or vested under an Award may be made subject to the attainment of performance goals. The Committee may utilize any performance criteria selected by it in its sole discretion to establish performance goals; provided, however, that in the case of any Award intended to qualify as “performance-based compensation” under Section 162(m) of the Code (“Performance Based Award”), the following conditions shall apply:

			
	
			
				 (i)
			The amount potentially available under a Performance Based Award shall be subject to the attainment of pre-established, objective performance goals relating to a specified period of service based on one or more of the following performance criteria: (a) cash flow (including operating cash flow), (b) earnings per share, (c) earnings before any combination of interest, taxes, depreciation or amortization, (d) return on equity, (e) total stockholder return, (f) share price performance, (g) return on capital, (h) return on assets or net assets, (i) revenue, (j) income or net income, (k) operating income or net operating income, (l) operating profit or net operating profit, (m) operating margin or profit margin (including as a percentage of revenue), (n) return on operating revenue, (o) return on invested capital, (p) market segment shares, (q) costs, (r) expenses, (s) achievement of target levels of discovery and/or development of products or services, including but not limited to research or regulatory achievements, (t) third party coverage and/or reimbursement objectives, (u) test volume metrics, (v) objective customer indicators (including, without limitation, customer satisfaction), (w) improvements in productivity, (x) attainment of objective operating goals, or (y) objective employee metrics (“Qualifying Performance Criteria”), any of which may be measured either individually, alternatively or in any combination, applied to either the individual, the Company as a whole or to a business unit or subsidiary of the Company, either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, or on the basis of any other specified period, on an absolute basis or relative to a pre-established target, to previous years’ results or to a designated comparison group or index, and subject to specified adjustments, in each case as specified by the Committee in the Award.

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  20  -

		

 

		

			 

		

		

			
	
			
				 (ii)
			Unless specified otherwise by the Committee at the time the performance goals are established or otherwise within the time limit prescribed by Section 162(m) of the Code, the Committee shall appropriately adjust the method of evaluating performance under a Qualifying Performance Criteria for a performance period as follows: (a) to exclude asset write-downs, (b) to exclude litigation or claim judgments or settlements, (c) to exclude the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported results, (d) to exclude accruals for reorganization and restructuring programs, (e) to exclude any extraordinary nonrecurring items as determined under generally accepted accounting principles and/or described in managements’ discussion and analysis of financial condition and results of operations appearing in the Company’s annual report to stockholders for the applicable year, (f) to exclude the dilutive and/or accretive effects of acquisitions or joint ventures, (g) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a performance period following such divestiture, (h) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends, (i) to exclude the effects of stock based compensation; and (j) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles, in each case in compliance with Section 162(m).

			
	
			
				 (iii)
			The Committee shall establish in writing the applicable performance goals (and any variation to the adjustments specified in the preceding subparagraph (ii)), and an objective method for determining the Award earned by a Participant if the goals are attained, while the outcome is substantially uncertain and not later than the 90th day of the performance period (but in no event after 25% of the period of service with respect to which the performance goals relate has elapsed), and shall determine and certify in writing, for each Participant, the extent to which the performance goals have been met prior to payment or vesting of the Award. The Committee may reserve the right, in its sole discretion,  to reduce the amount of compensation otherwise payable under the Plan upon the attainment of the pre-established performance goals. The Committee may not in any event increase the amount of compensation payable under the Plan upon the attainment of the pre-established performance goals to a Participant who is a “covered employee” within the meaning of Section 162(m) of the Code.

			
	
			
				 SECTION 18.
			

			
	
			
			NO EMPLOYMENT RIGHTS.

		
			No provision of the Plan, nor any right or Option granted under the Plan, shall be construed to give any person any right to become, to be treated as, or to remain an Employee. The Company and its Subsidiaries reserve the right to terminate any person’s Service at any time and for any reason, with or without notice.
		

		
			

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  21  -

		

 

		

			 

		

		

			
	
			
				 SECTION 19.
			

			
	
			
			DURATION AND AMENDMENTS.

			
	
			
				 (a)
			Term of the Plan. The Plan, as set forth herein, shall terminate automatically on March 18,  2024 and may be terminated on any earlier date pursuant to Subsection (b) below.

			
	
			
				 (b)
			Right to Amend or Terminate the Plan. The Board of Directors may amend or terminate the Plan at any time and from time to time. Rights and obligations under any Award granted before amendment of the Plan shall not be materially impaired by such amendment, except with consent of the Participant. An amendment of the Plan shall be subject to the approval of the Company’s stockholders only to the extent required by applicable laws, regulations or rules.

			
	
			
				 (c)
			Effect of Termination. No Awards shall be granted under the Plan after the termination thereof. The termination of the Plan shall not affect Awards previously granted under the Plan.

		 

		

			Genomic Health, Inc.

		

		

			Amended and Restated 2005 Stock Incentive Plan

		

		

			-  22  -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]